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In emerging domains, such as precision oncology, knowledge extracted from explicit 
assertions may be insufficient to identify relationships of interest. One solution to this 
problem involves drawing inference on the basis of similarity. Computational methods 
have been developed to estimate the semantic similarity and relatedness between terms and 
relationships that are distributed across corpora of literature such as Medline abstracts and 
other forms of human readable text. Most research on distributional similarity has focused 
on the notion of attributional similarity, which estimates the similarity between entities 
based on the contexts in which they occur across a large corpus. A relatively under-
researched area concerns relational similarity, in which the similarity between pairs of 
entities is estimated from the contexts in which these entity pairs occur together. While it 
seems intuitive that models capturing the structure of the relationships between entities 
might mediate the identification of biologically important relationships, there is to date no 
comparison of the relative utility of attributional and relational models for this purpose.  
In this research, I compare the performance of a range of relational and attributional 
similarity methods, on the task of identifying drugs that may be therapeutically useful in 
the context of particular aberrant genes, as identified by a team of human experts. My 





as a means to identify biological relationships that may provide answers to clinical 
questions, (such as “which drugs INHIBIT gene x”?) in the context of rapidly evolving 
domains. 
My results show that models based on relational similarity outperformed models based on 
attributional similarity on this task. As the methods explained in this research can be 
applied to identify any sort of relationship for which cue pairs exist, my results suggest that 
relational similarity may be a suitable approach to apply to other biomedical problems. 
Furthermore, I found models based on neural word embeddings (NWE) to be particularly 
useful for this task, given their higher performance than Random Indexing-based models, 
and significantly less computational effort needed to create them. NWE methods (such as 
those produced by the popular word2vec tool) are a relatively recent development in the 
domain of distributional semantics, and are considered by many as the state-of-the-art 
when it comes to semantic language modeling. However, their application in identifying 
biologically important  relationships from Medline in general, and specifically, in the 
domain of precision oncology has not been well studied. 
The results of this research can guide the design and implementation of biomedical 
question answering and other relationship extraction applications for precision medicine, 
precision oncology and other similar domains, where there is rapid emergence of novel 
knowledge. The methods developed and evaluated in this project can help NLP 
applications provide more accurate results by leveraging corpus based methods that are by 
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Chapter 1: Introduction 
Background 
Biomedical literature is growing rapidly. In 2015 alone, more than 870,000 publications 
were added to, and indexed in Medline (Figure 1).(“MEDLINE Citation Counts by Year 
of Publication,” n.d.). Clinicians and other researchers that look for specific answers to  
 
 
Figure 1. Medline citations by year. 
 
their questions may be faced with overwhelmingly large sets of documents returned by 





from text (such as Question Answering - QA systems) rather than documents that may 
contain the relationships of interest have the potential to address this problem. However, 
the majority of those systems rely on well-established knowledge resources (such as known 
relations between concepts (At, 1989)) to extract information from the biomedical 
literature. (Athenikos & Han, 2010) Rapidly evolving domains (such as precision 
oncology) pose unique challenges to QA and other relationship extraction systems. Due to 
the rapid emergence of new knowledge in these domains  (such as discovery of new drugs 
or new molecular targets), the resources found in the clinical literature are scarce by 
definition, and systems such as SemRep, a Natural Language Processing (NLP) system for 
biomedical literature, which are optimized for precision, and rely solely on knowledge 
extracted from explicit assertions (such as “rapamycin inhibits mtor”) may miss 
relationships of interest. (Fathiamini et al., 2016) 
It has been argued that methods that infer relationships between biomedical concepts by 
examining the ways in which they are distributed across large text corpora, present a robust 
and desirable alternative (Percha & Altman, 2015). In these approaches, generally known 
as methods of “distributional semantics”, similar representations are generated for terms 
that occur in similar contexts in the literature, (Trevor Cohen & Widdows, 2009) and the 
similarity between concepts of interest can be measured.  
Most research on distributional similarity has focused on the notion of attributional 
similarity, which estimates the similarity between entities (such as two drugs). However, 





Therefore, relational similarity, the estimation of the similarity between pairs of entities 
(such as two drug-gene pairs) based on the nature of the relationship between them is 
important. Relational similarity is estimated from the contexts in which these entity pairs 
occur together, and may help identify interesting relationships between biomedical 
concepts. However, within biomedicine scant research exists on this topic. Methods for 
estimation of relational similarity have seldom been evaluated, and little is known about 
how these methods might be leveraged for QA purposes in emerging domains. 
Hypothesis and Specific Aims 
The dissertation explores the utility of a scalable corpus-based approach to estimate the 
relational similarity between pairs of concepts extracted from Medline abstracts. My 
hypothesis is that relational similarity will be of greater utility than attributional similarity 
as a means to identify biological relationships that may provide answers to clinical 
questions, (such as “which drugs INHIBIT gene x”?) in the context of rapidly evolving 
domains. 
In the context of the application domain of precision oncology, I evaluate this hypothesis 
using sets of known relationships as seeds, and attempting to generalize from them using 
both attributional (which drugs are similar to the known inhibitors of x?) and relational 
(which drugs relate to gene x in a similar manner to known inhibitors of x?) similarity, 





Aim 1: Develop and implement models of attributional and relational 
similarity 
Models of relational and attributional similarity are developed using two widely-used 
distributional semantics techniques: Random Indexing (M. Sahlgren, 2005) (RI) and 
Neural Word Embeddings (Mikolov, Chen, Corrado, & Dean, 2013; Mikolov, Yih, & 
Zweig, 2013) (NWE).   
Aim 1.1 Relational similarity.  
With RI, I explicitly identify drug-gene pairs, and derive vector representations of these 
concept pairs from the terms that occur between them. The similarity between the resulting 
pair vectors is used to draw inference about previously unseen pairs. With NWE, I use 
implicit relational information by performing geometric operations on concept vectors 
(𝐷𝑟𝑢𝑔𝑐𝑢𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ − 𝐺𝑒𝑛𝑒𝑐𝑢𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  + 𝐺𝑒𝑛𝑒𝑡𝑎𝑟𝑔𝑒𝑡⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ≅ ? (Mikolov, Chen, et al., 2013). Relational 
similarity is estimated as the cosine metric between the vector resulting from these 
operations, and the NWE vector for a candidate drug. 
Aim 1.2 Attributional similarity.  
With both RI and NWE I use Medline abstracts as documents to build vector spaces, and 






Aim 2: Recovery of held-out drug/gene relationships 
Using a reference set of clinically-relevant drug/gene relationships developed for precision 
oncology, the models from SA1 are evaluated for their ability to recover held-out 
relationships given a set of seed examples, across a broad range of cross-validation 
configurations. 
Aim 3: Unsupervised identification of clinically relevant drug/gene 
relationships 
As implemented to meet Aim 2, relational similarity models require a set of expert-
generated “seed” examples to serve as cues. As these examples may be unavailable at the 
outset of a project, in this Aim I develop and evaluate an alternative proposal in which cues 
are derived without expert input, using knowledge extracted from the biomedical literature 
using NLP. The attributional and relational models developed in Aim 1 are evaluated for 
their performance, using a reference set of clinically-relevant drug/gene relationships. 
Biomedical relevance 
Although the methods developed and evaluated in this dissertation should be applicable to 
identifying biomedically meaningful relationships in general, I have selected Precision 
Oncology, the use of molecular characteristics of a tumor and patient attributes, to 
“personalize” therapy, as an application domain on account of the pressing need for 
identification of clinically relevant drug/gene relationships in this domain. (Garraway, 





2013) To support clinical decisions, domain experts must continuously review the 
published literature to develop and maintain a knowledge base of cancer-related genes, and 
the agents that target these genes or their associated biological pathways. (Johnson et al., 
2015) With both the number of genes and the relevant literature growing rapidly, manual 
review of the literature in search of new therapies is not scalable, and there is a pressing 
need for informatics technologies to help curators more rapidly retrieve and review relevant 
biomedical literature. (Johnson et al., 2015; Meric-Bernstam et al., 2013) The methods 
developed and evaluated in this project can serve as an important step toward that goal.  
Guide for the reader  
The remainder of this dissertation proceeds as follows. Chapter 2 provides an in-depth 
review of the literature on distributional semantics, relational and attributional similarity, 
theoretical and cognitive basis of relational similarity, question answering, and informatics 
needs of precision oncology. Chapter 3 describes the details of my preliminary 
experiments, and in particular AIMED(Fathiamini et al., 2016), an application built to 
retrieve drug/gene relationships from biomedical text, which elucidates some of the 
challenges of this task in the domain of precision oncology, and helps form a basis for the 
next experiments. Chapter 4 reports on the details and results of the Specific Aims 1, and 
2 of the research. Chapter 5 discusses the results of the Specific Aim 3, and their 
significance. Chapter 6 summarizes the accomplishments, contributions of the research 










Chapter 2: Literature Review 
As explained in Chapter 1, the focus of this research is on a comparative analysis of a range 
of relational and attributional similarity techniques – components of the broader field of 
distributional semantics – and the application domain I have selected in which to do this 
evaluation is precision oncology. As part of my preliminary studies to better understand 
the characteristics and informatics requirements in this field, I created a 
Question/Answering (QA) application to help a team of curators find the answers to their 
questions of type “What drugs inhibit gene X?”, and maintain a knowledge base of drug-
gene relationships. This project helped elucidate some of the unique challenges of this task 
in the domain of precision oncology, and led us to realize the need for the current research. 
Some of the text in this chapter is borrowed from our published paper from this project. 
(Fathiamini et al., 2016) 
To follow the natural progression of ideas that led to the conception of the current research, 
I will present my findings from the existing literature in the following order: First I will 
briefly discuss QA systems, with a focus on biomedical QA, and in particular, as it applies 
to emerging domains such as precision oncology. Next, I will touch on techniques of 
relationship extraction, and make a case of why methods of distributional semantics may 





relational and attributional similarity methods, and explain the need for further research in 
this domain.   
The challenge of biomedical information retrieval 
The biomedical literature often contains answers to clinicians’ clinical and research 
questions, (Westbrook, Coiera, & Gosling, 2005; WESTBROOK, GOSLING, & 
PSYCHD, 2004) and clinicians believe that the quality of patient care could be improved 
by online search.(WESTBROOK et al., 2004) However, the answers to two-thirds of the 
questions that clinicians have about their patients are either not pursued, or pursued but not 
found. (Chambliss & Conley, 1996; Currie et al., 2003; Huang, Lin, & Demner-Fushman, 
2006) Further analysis shows that poorly constructed queries is one of the main reasons 
why the right answers cannot be found. (Demner-Fushman & Lin, 2007; Gorman & 
Helfand, 1995) Besides, given the overwhelming size of the documents that are often 
returned by PubMed/MEDLINE, identifying relevant citations can be difficult, and 
advanced features such as Boolean combinations of MeSH terms are seldom used.(Haynes 
et al., 1990; Herskovic, Tanaka, Hersh, & Bernstam, 2007) Also physicians may be 
concerned about existence of answers, have time limitations, or have doubts about the 
optimal search strategy.(Ely, Osheroff, Chambliss, Ebell, & Rosenbaum, 2005; Ely et al., 
2002) They spend much less time searching for an answer than would be required to find 
one.(Ely et al., 1999; W. R. Hersh et al., 2002) In general, the ability of the users to find 
answers to their clinical questions using Medline is low. (W. R. Hersh et al., 2002) QA 





Biomedical QA systems 
Traditionally, document retrieval systems (such as PubMed) return a list of documents in 
response to a user’s query. However, this requires manual review of each document. So, 
QA systems that return structured knowledge (e.g., drug A targets gene B) with links to 
supporting documents are a desirable alternative.(Athenikos & Han, 2010; W. R. Hersh & 
SpringerLink (Online service), 2009; Voorhees, 2001) Given the rapid growth of online 
literature, it has been argued that QA capabilities are among the most critical features of 
future search engines.(Athenikos & Han, 2010) QA systems try to provide accurate 
answers to their questions by integrating Natural Language Processing (NLP), text 
summarization, information extraction, and statistical and knowledge-based 
methods.(Demner-Fushman, Chapman, & McDonald, 2009; Hirschman & Gaizauskas, 
2001) Early QA systems only relied on term based methods to generate answers. However, 
due to the availability of vast amounts of biomedical information, and its crucial role in 
research and applications, there was a growing need for better QA systems that could help 
researchers and healthcare professionals in their search for answers to their questions. 
(Athenikos & Han, 2010) As such, biomedical QA systems moved beyond the surface level 
term based analysis, drawing on knowledge-based ontological resources.(Athenikos & 
Han, 2010)  
Knowledge-based QA systems 
A wealth of knowledge resources, including ontologies, have been developed in 





complex queries, and there is evidence that they are of value for QA. (Rinaldi, Dowdall, & 
Schneider, 2004; Yu & Sable, n.d.; Zweigenbaum, 2003, 2009) To provide accurate 
answers, most QA systems in biomedicine draw upon these curated knowledge sources 
(such as the Unified Medical Language System or UMLS), and leverage the reasoning 
capabilities that ensue to address issues such as ambiguity and synonymy, and also 
facilitate cross document or cross knowledge-base queries using inference.(Athenikos & 
Han, 2010; Lopez, Motta, Uren, & Sabou, 2007) Analysis of the TREC Genomics Track 
(“TREC Genomics Track,” n.d.), which focused solely on biomedical content and was one 
of the largest challenge evaluations in biomedical QA, showed that normalization of query 
terms and use of the Entrez Gene thesaurus for synonym expansion, post-filtering answers, 
and the option to specify answer entity types (e.g., genes, proteins, diseases, etc.) were 
among the factors associated with higher performance. (W. Hersh, Cohen, Ruslen, & 
Roberts, 2007; MOLDOVAN, CA, HARABAGIU, & SURDEANU, 2003; Rekapalli, 
Cohen, & Hersh, 2006)  
However, structured knowledge alone is not adequate to obtain state-of-the-art 
performance. The majority of medical QA system use a combination of knowledge based 
and statistical methods to find their answers.(Athenikos & Han, 2010) For example, CQA-
1.0 (Demner-Fushman & Lin, 2007) is a semantics-based medical QA system based on the 
PICO framework – a guideline of evidence-based medicine (EBM), stating that 
constructing a clinical question in terms of the four areas of Problem/Population, 





answer (Richardson, Wilson, Nishikawa, & Hayward, 1994). It uses a combination of 
statistical methods (including supervised machine learning) and knowledge-based 
techniques (leveraging the UMLS and MetaMap (Aronson, n.d.)) to identify relevant 
Medline abstracts, ranks them using a multi-step scoring system, and returns short passages 
as answers. Essie (Ide, Loane, & Demner-Fushman, 2007) is a probabilistic search engine 
developed at the National Library of Medicine for the ClinicalTrials.gov database, and 
provide a concept-based search using UMLS-derived synonymy, document relevance 
ranking using positional information (such as location in the document with regard to 
different sections) of the search phrase, and query expansion using UMLS SPECIALIST 
lexicon (McCray, Srinivasan, & Browne, 1994). Essie was the best performing search 
engine in 2003 TREC Genomics track (SNEIDERMAN, DEMNER-FUSHMAN, 
FISZMAN, IDE, & RINDFLESCH, 2007), and one of the best in 2006. (Ide et al., 2007) 
SEM-BT (Hristovski, Dinevski, Kastrin, & Rindflesch, 2015) is a biomedical search engine 
that implements QA as a search in a database of semantic relations, extracted from 
biomedical literature by SemRep NLP system (Rindflesch & Fiszman, 2003), a natural 
language processing tool developed at the National Library of Medicine. SemRep depends 
upon both MetaMap (Aronson, n.d.) and knowledge encoded in the UMLS.(Bodenreider, 
2004) MiPACQ (Cairns et al., 2011) is a clinical QA systems that integrates multiple 
Natural Language Processing (NLP) components to achieve deep semantic understanding 
of medical questions and texts. MiPACQ provides query formulation, automatic question 
and candidate answer annotation, and machine learning (ML) based answer re-ranking. 





clinical questions and outputs question-focused extractive summaries as answers. The 
system indexes five types of resources: MEDLINE abstracts, PubMed Central full-text 
articles, eMedicine documents, clinical guidelines and Wikipedia articles. In an experiment 
three systems (SemRep, Essie, and CQA-1.0) were examined in combination, to determine 
how traditional information retrieval (Pubmed search) could be improved using 
knowledge-based methods in a hybrid approach to question answering. Those systems used 
varying degrees of semantic knowledge, and overall, combining those methods resulted in 
better system performance than that of individual systems.(SNEIDERMAN et al., 2007)  
There are medical QA systems that do not employ a knowledge-based approach. MedQA 
(Lee et al., 2006) for example, uses a syntactic parser for question classification, standard 
IR methods for document retrieval, and syntactic and statistical techniques such as 
document zone detection and clustering for answer extraction. Still, the creators of this 
system recognize the need for a domain specific parser and the importance of capturing 
semantic information, and the need for UMLS concepts and semantic types to help classify 
questions more effectively. (Yu & Cao, 2008; Yu, Sable, & Zhu, n.d.) What these systems 
have in common is reliance on domain-specific knowledge resources. This dependence is 
likely to be a liability in emerging domains.  
Medical QA in emerging domains 
The application domain I have selected in which to evaluate the relative merits of 
attributional and relational similarity is precision oncology. This task-domain is different 





QA systems follow an EBM-based approach, and try to provide answers supported by 
extensive evidence. In rapidly evolving domains such as precision oncology, the resources 
found in the clinical literature are often scarce, and relation extraction systems that rely on 
well-established knowledge and favor precision over recall (such as SemRep) may miss 
valuable information (On average, SemRep provides a precision of around 77% across 
different experiments (Kilicoglu et al., 2008), and in one study its recall was around 55%. 
(Ahlers, Fiszman, Demner-Fushman, Lang, & Rindflesch, 2007)) Further, in order to 
provide accurate answers, medical QA systems often draw upon manually constructed 
ontologies and leverage semantic classes or domain specific typology of questions to 
provide more accurate answers, or limit the size of their result sets. However, the utility of 
such semantic resources is restricted to topics where the concepts and relationships have 
already been defined, usually based on well-established knowledge. Due to the rapid 
emergence of new knowledge in emerging domains, there is often a knowledge gap 
between the newly discovered entities and relationships, and those described in existing 
ontologies (in precision oncology, an example might be discovery of new drugs that are 
yet to be added to existing drug ontologies). Furthermore, knowledge from both the 
literature (including clinical and cancer biology) and other sources (such as clinical trials 
or pharmaceutical companies) may be relevant, which presents additional challenges for 
the technologies employed. For example, pharmaceutical companies do not expose their 
drug annotations as structured data, and the need to extract this information from web pages 





As part of preliminary experiments to partially address this problem, we introduced the 
AIMED system (Fathiamini et al., 2016) (explained in Chapter 3). In this system, I showed 
that the knowledge-driven SemRep biomedical NLP system was only beneficial for finding 
established drugs, whereas with investigational agents, the performance was better when 
using co-occurrence counts without the use of NLP (other than for concept extraction and 
normalization). However, while recall improved with the use of co-occurrence, precision 
decreased since extracted relationships were no longer constrained. These results revealed 
an underexplored area between the linguistic rules and semantic constraints that systems 
such as SemRep impose to identify specific relationships on the one hand (thus achieving 
higher precision), and the unconstrained associations defined by co-occurrence (evident by 
higher recall) on the other. In the absence of established relationships as the underlying 
knowledge to constrain Boolean retrieval, the co-occurrence result sets can be 
overwhelmingly large. One approach to this problem involves applying relationship 
extraction techniques to find only those relations that are relevant to the query. A general 
overview of relationship extraction is discussed next. 
Relationship extraction 
There is a large body of research concerning relationship extraction (RE), and NLP 
methods that can analyze text and find the relationships of interest in biomedical 
domains.(Friedman, Kra, Yu, Krauthammer, & Rzhetsky, 2001; Fundel, Küffner, & 
Zimmer, 2006; Kotecki & Cochran, 2002; McDonald et al., 2005; Rindflesch & Fiszman, 





types. The relationship can be general (like any biological relationship) or specific (such 
as an INHIBITS relation).(A. M. Cohen & Hersh, 2005) Biomedical RE is often considered 
a sentence level problem which relies on rules or ontologies that map terms to standard 
concept representations such as UMLS Concept Unique Identifiers (CUIs). Maintaining 
these representations, and subsequently, building bio-medically relevant models based on 
them (that need to be rebuilt for each new domain) is time consuming and requires constant 
human supervision and effort.(Trevor Cohen & Widdows, 2009) Due to inaccuracies in the 
NLP process in general, and RE from the biomedical literature in particular, many 
biomedical knowledge bases such as PharmGKB and DrugBank are entirely based on 
manual curation.(Percha & Altman, 2015) My Cancer Genome is another example of a 
manually curated knowledge base that provides precision oncology related resources.(“My 
Cancer Genome, Genetically Informed Cancer Medicine,” n.d.) Similarly, the Drug-Gene 
Interaction database (DGIdb) is a database of potentially druggable genes aggregated from 
multiple other resources including My Cancer Genome and other manually curated 
databases.(Griffith et al., 2013) Another set of techniques for sentence level RE apply 
machine-learning methods, avoid rules, but require annotated sentences for training. Such 
annotation is time consuming and human intensive.(Kim, Ohta, Tateisi, & Tsujii, 2003) 
Linguistic patterns (such as regular expressions) have been used for RE, either as 
prescribed by domain experts, or automatically by generalizing patterns from training sets 
and searching among sentences to find commonalities. These methods take a long time to 
process text and generate results, especially with large pattern sets. (A. M. Cohen & Hersh, 






In contrast to sentence-level approaches, statistical methods have been applied to find 
concepts that co-occur with each other more frequently than would be observed by chance. 
It has been argued that this corpus-based approach provides a more robust mechanism for 
finding relationships of interest, as it infers relationships from the overall distribution of 
terms across an entire corpus of text, rather than from an individual assertion.(Percha & 
Altman, 2015) These methods, collectively known as distributional semantics (Trevor 
Cohen & Widdows, 2009; Levy, Goldberg, Dagan, & Ramat-Gan, 2015) correspond to 
cognitive models of memory recall (Trevor Cohen & Widdows, 2009; Kanerva, 2010; 
Landauer, Foltz, & Laham, 1998; LUND & BURGESS, n.d.), and match well to human 
judgment of pairwise correlation between biomedical concepts. (McInnes & Pedersen, 
2017; Pakhomov, Finley, McEwan, Wang, & Melton, 2016) They provide fast and robust 
mechanisms to find relatedness and similarity between concepts and relations (Trevor 
Cohen & Widdows, 2009), and have been used to identify relationships between entities. 
(Lin & Pantel, 2001; Riedel, Yao, Marlin, & McCallum, 2013) These models can also 
capture information concerning the nature of the relationships between terms, either 
incidentally (Mikolov, Yih, et al., 2013), or by design (Turney, 2005). An important 
distinction concerning the nature of the estimates derived from these models is that between 





Attributional similarity  
The majority of the research on distributional semantics has focused on attributional 
similarity – similarity between objects or their properties. (Medin, Goldstone, & Gentner, 
1990)  That is to say, distributional methods have been developed and evaluated for their 
ability to capture the similarity between conceptually-related entities. This is possible 
because distributional methods enable the estimation of a quantitative measure of semantic 
relatedness between terms from the contexts in which they occur in across a large corpus 
of text. Geometric approaches to this problem involve the derivation of reduced-
dimensional (i.e. with dimensionality less than the number of unique contexts, or context 
terms in a corpus) vector representations of terms from the contexts in which they occur 
(Turney & Pantel, 2010), such that terms that occur in similar contexts will have similar 
vector representations. The distance between the resulting vectors provides a meaningful 
estimate of semantic similarity and relatedness. Such approaches include (but are not 
limited to) Latent Semantic Analysis (LSA) (Landauer & Dumais, 1997), and the 
Hyperspace Analogue to Language (HAL) (Lund & Burgess, 1996), which have been used 
to find similarity between terms and documents with good correspondence with human 
performance across a range of cognitive tasks. (Landauer et al., 1998; LUND & 
BURGESS, n.d.) Another method, Random Indexing (M. Sahlgren, 2005) generates a 
reduced dimensional space and produces similar results to LSA in evaluations of the quality 
of term-term similarity such as synonym tests, and correspondence with free association 





much less computational power.(Trevor Cohen & Widdows, 2009; M. Sahlgren, 2005) 
These methods have been applied to problems such as information retrieval (Deerwester, 
Dumais, Furnas, Landauer, & Harshman, n.d.), literature-based knowledge discovery 
(Gordon & Dumais, 1998), bilingual information extraction (Widdows et al., 2003), and 
relationship extraction (Pedersen, Pakhomov, Patwardhan, & Chute, 2007). More recently, 
neural word embeddings (Mikolov, Chen, et al., 2013; Mikolov, Yih, et al., 2013) have 
become a popular method of generating such reduced-dimensional representations, with 
improvements over prior distributional methods in some evaluations (Baroni, Dinu, & 
Kruszewski, 2014) (although some of these improvements have been shown to be 
contingent upon optimal configuration of model hyper-parameters in subsequent 
experiments (Levy et al., 2015)). 
Relational similarity 
Relational similarity, on the other hand, involves similarity between any two given pairs 
of concepts – if A’s relationship to B is similar to C’s relationship to D, then A::B is in 
relational similarity to C::D. Theories of analogy seem to agree that relational similarity is 
a fundamental component of analogical reasoning. (GENTNER, 1988; Medin et al., 1990; 
Medin, Goldstone, & Gentner, 1993) According to those theories, similarity requires a 
point of reference – one must specify the aspect from which two things are similar (e.g. 
drugs can be similar based on their clinical effect, chemical composition, etc.) – and in the 
case of relational similarity, the relational commonalities provide the relevant aspect of 





(Goodman, 1972; HOLYOAK & THAGARD, 1989; Medin et al., 1993) In the section that 
follows, I review some of the recent work in distributional semantics that has attempted to 
estimate structural similarity of this sort from text directly.  
In seminal work in this area, Turney and Littman created a Vector Space Model (VSM) for 
calculating relational similarity.(Turney & Littman, 2005) Sixty-four “joining words” 
(such as “for”, “of”, “to”, etc.) were used to create patterns of both “A join B” and “B join 
A” (such as “A of B”, “B of A”, etc.). Then, they characterized the relationship between 
two words (A and B) by counting the number of times they appeared in those patterns 
across the corpus, which yielded a vector of 128 numbers for each A::B relationship of 
interest. The relational similarity between any two given pairs of words was then 
represented by the cosine similarity between their corresponding vectors.(Turney & 
Littman, 2005) This work was then extended by Turney to develop Latent Relational 
Analysis (LRA) [47], a technique for measuring relational similarity that adapts the VSM 
model in three ways: 1) patterns are extracted from the corpus dynamically by finding 
exemplar phrases that involve the pair of interest, 2) a thesaurus is used to extend the search 
space by including words that are similar to the query terms (the pair), and 3) in a manner 
reminiscent of LSA, Singular Value Decomposition (SVD) is used for dimension reduction 
of the resulting pair-by-pattern matrix.(Turney, 2005) As such, LRA may be inconvenient 
to implement, particularly when pairs of interest change frequently and the text corpus is 
large, and may scale poorly to large sets of concept pairs on account of the need to apply 





374 analogy test questions, running on a matrix of 8,000 columns and 17,232 rows (48 
pairs per question, with some omissions). Although the software was not optimized for 
speed (Turney, 2005), and the decomposition would no doubt run faster on contemporary 
hardware, decomposing a matrix with as many rows as there are concept pairs of interest 
is a computationally inconvenient feature of this model. 
Recent work in the general domain has attempted to estimate relational similarity from 
term (rather than pair) vector representations directly, finding that word vectors derived 
from a scalable neural network model can implicitly capture information of this sort. 
Specifically, Mikolov and his colleagues developed two neural network architectures, 
continuous bag of words (CBOW) (which learns to predict a word based on the words that 
surround it), and the continuous skip-gram model (which learns to predict context words 
based on an observed word). These “word embedding” architectures were used to train 
word representations from large corpora (billions of words), and the resulting word vectors 
were shown to capture relationships between words, which could be recovered with simple 
geometric operations. For example, using the resulting vector representations, 𝑃𝑎𝑟𝑖𝑠⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ −
𝐹𝑟𝑎𝑛𝑐𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ + 𝐺𝑒𝑟𝑚𝑎𝑛𝑦⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ≅ 𝐵𝑒𝑟𝑙𝑖𝑛⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗.(Mikolov, Chen, et al., 2013; Mikolov, Yih, et al., 2013) 
Training of these architectures occurs through a process of online learning (Shalev-
Shwartz, 2011), in which each training context (a “sliding window” of words surrounding 
each observed word) is considered independently (though global term frequency statistics 
are used to inform subsampling strategies).  This permits parallel implementation of the 





to capture such relational information without training a predictive model (such as a neural 
network) on an example-by-example basis. Specifically, Pennington et al. introduce Global 
Vectors (GloVe (Pennington, Socher, & Manning, 2014)), a model for the unsupervised 
learning of word representations that utilizes global distributional statistics directly, while 
nonetheless capturing similar structural information to online neural-probabilistic methods. 
In some experiments, GloVe performed better than comparable neural network approaches 
in evaluations on pairwise analogies (Pennington et al., 2014), however these advantages 
were not replicated in subsequent experiments in which hyperparameters and training 
corpora were consistent across models (Levy et al., 2015).   
 Some research on relational similarity exists in the biomedical domain. Predication-based 
Semantic Indexing (PSI) is a variant of Random Indexing that explicitly encodes 
relationships between concepts from a collection of semantic predications (such as those 
extracted by SemRep, for example docetaxel STIMULATES akt) into distributed vector 
representations of these concepts.(Trevor Cohen, Schvaneveldt, & Rindflesch, 2009; 
Trevor Cohen, Widdows, Schvaneveldt, Davies, & Rindflesch, 2012; Widdows & Cohen, 
2015) Across several experiments (see for example (T. Cohen et al., 2014; Trevor Cohen 
et al., 2012; Shang, Xu, Rindflesch, & Cohen, 2014), and for a review in (Widdows & 
Cohen, 2015)), PSI was applied to infer previously unseen relationships by using relational 
similarity, including both harmful and potentially therapeutic drug/effect 
relationships.(Trevor Cohen, Widdows, Schvaneveldt, & Rindflesch, 2011) Embedding of 





advantages in predictive modeling experiments using estimates of relational similarity. 
(Trevor Cohen & Widdows, 2017) Both PSI and ESP use relations extracted by SemRep 
rather than free text, and thus represent a different class of methods to those under 
consideration in the current work. 
Of particular relevance to the current work, Percha and Altman developed a method that 
uses grammatical dependency paths in the sentences that contain a pair of concepts as 
contextual features. (Percha & Altman, 2015) An unsupervised clustering technique called 
Ensemble Biclustering for Classification (EBC) is then applied to the resulting pair-by-
path matrix, such that drug-gene pairs are represented by their frequencies of co-clustering 
with every other pair across large numbers of stochastically-initialized clustering 
processes. As drug/gene pairs linked by similar dependency paths will cluster together, 
EBC leverages relational similarity drawn from distributional statistics. Using a seed set of 
ten drug-gene relationships, EBC was shown to successfully detect similar relations from 
a large corpus of Medline abstracts.(Percha & Altman, 2015) The relations identified in 
this process were recently made publicly available (Percha, Altman, & Wren, 2018a). 
Because operates in a largely unsupervised manner, EBC is not readily adaptable to the 
cue/response paradigm I employ in the current evaluation, which is limited to methods that 
do not require parsing to reveal grammatical dependencies. 
Summary of research on relational similarity 
The techniques discussed above have been mostly applied in the general domain, resulting 





embeddings, that can be used to create relational similarity models without requiring 
computationally demanding techniques of dimension reduction. Given the size of the 
pharmacogenomics search space, this is an important consideration. PSI and ESP are 
similarly scalable, but explicitly encode relations extracted by SemRep, and therefore are 
in a different methodological category to those methods attempting to infer relational 
information from free text directly. Dealing with text directly is a desirable alternative in 
emerging domains, on account of the time lag in the incorporation of emerging drugs into 
the knowledge sources upon which NLP systems such as SemRep depend, and the fact that 
SemRep’s optimization for precision over recall is not ideal for concepts that appear in a 
small number of citations only. EBC searches for the relational similarity between drug-
gene pairs by applying distributional techniques across Medline abstracts, but uses only 
one type of linking relationship (dependency paths), and has not been evaluated against an 
attributional counterpart. While it seems intuitive that relational similarity would be better 
suited to recognition of biomedical relationships than attributional similarity, this 
hypothesis has not been tested. 
Overall, there is an opportunity for further research to identify techniques based on 
relational similarity to identify meaningful drug/gene relationships in emerging biomedical 
domains. The current research explores the application of relational and attributional 
similarity techniques in precision oncology, as an exemplar of an emerging biomedical 









Chapter 3: Preliminary experiments – Automatic Identification of Molecular Effects 
of Drugs (AIMED) 
My preliminary work examines the utility of relatively constrained semantic relationships 
versus relatively unconstrained co-occurrence statistics. The results of this research 
revealed an underexplored area between these two ends of the relationship extraction 
spectrum, and motivated the development of a hypothesis that forms the theoretical basis 
for this dissertation. The evaluation explained in this chapter was conducted in the context 
of a QA system I developed to find relevant drug-gene relationships in the context of 
precision oncology, which provides the practical motivation for the specific aims of this 
dissertation. Some sections in this chapter are borrowed from my previously published 
paper (Fathiamini et al., 2016).  
Precision oncology 
Precision oncology, or personalized cancer therapy, involves the use of molecular 
characteristics of a tumor and patient attributes, to “personalize” therapy with the goal of 
more effective and less toxic cancer treatment.(Garraway et al., 2013; Meric-Bernstam et 
al., 2013) Therapy can be personalized using different aspects, including a specific 
patient’s exposure history, preferences and clinical features. However, genomic profiling 





cancer patients, and can help select “genomically-informed” targeted therapy options, and 
oncologists can prescribe treatment targeted to specific molecular aberrations found in a 
patient’s tumor. 
To support clinical decisions, domain experts must continuously review the published 
literature to develop and maintain a knowledge base of cancer-related genes, and the agents 
that target these genes or their associated biological pathways.(Johnson et al., 2015) 
Personalizedcancertherapy.org is one such knowledge base that can serve as a reference 
for clinicians.(Johnson et al., 2015) Existing technologies that extract knowledge from the 
biomedical literature are generally designed for stable domains where the state of 
knowledge evolves relatively slowly. For example, one analysis found that 90% of clinical 
practice guidelines were still valid at 3.6 years. (Shekelle et al., 2001) In contrast, precision 
oncology evolves much more rapidly. As information concerning newer agents is relatively 
scarce, established relation extraction systems that rely on established knowledge resources 
and favor precision over recall (such as SemRep (Rindflesch & Fiszman, 2003), an NLP 
tool developed at the National Library of Medicine) may miss valuable information. 
Further, many targeted therapies are investigational and are currently available primarily 
via clinical trials. Thus, there is an urgent need to develop informatics technologies to help 
curate pertinent clinical information. 
To this end, I developed a system for the Automated Identification of Molecular Effects of 
Drugs (AIMED), which leverages semantic information extracted by the SemRep and 





results and drug-gene co-occurrence data to extract clinically relevant pharmacogenomic 
relationships from the biomedical literature.  
Materials 
In this section I introduce the tools and materials that I have used to create AIMED.  
SemRep_UTH, a modified version of SemRep 
I designed and implemented a semantic QA system based on a large collection of 
predications that is publicly available in SemMedDB,(Kilicoglu, Shin, Fiszman, 
Rosemblat, & Rindflesch, 2012) which is generated by SemRep processing of Medline 
abstracts. Semantic predications in SemMedDB are organized as Subject-Predicate-Object 
triples, with subjects and objects being UMLS concepts, and predicates coming from 
UMLS Semantic Network. The Semantic Network defines allowable relationship types 
between any two concepts, based on their semantic type. (At, 1989) In early experiments I 
realized that many of the drugs that were relevant to precision oncology were 
underrepresented in this database. A search for some of these drugs (such as AZD2014) in 
online versions of interactive SemRep and MetaMap (accessible at (“Interactive SemRep,” 
n.d.) and (“Interactive MetaMap,” n.d.), respectively) revealed that SemRep by default uses 
a rather old version of UMLS (2006), and it “suppresses” some of the short forms of drug 
names, many of which relevant to my work (for example, AZD2014 was only recognizable 
by MetaMap, and so SemRep, in its full form as “mTOR Kinase Inhibitor AZD2014”). To 
address this problem, I updated SemRep’s data files to the latest version of the UMLS at 





the MRCONSO.RRF file. First I identified terms with both SAB (Abbreviated Source 
Name) value equal to ‘NCI’ (National Cancer Institute) and with TTY (Term Type) value 
equal to ‘CCN’ (Chemical Code Name) (henceforth: NCI/CCN). For NCI/CCN terms, I 
changed the ‘SUPPRESS’ value from ‘Y’ to ‘N’. This caused those terms to become 
‘active’ and therefore be useable by MetaMap and SemRep. Also, for NCI/CCN terms I 
changed the value of TS (Term Status) to ‘P’ (‘Preferred’) where they were ‘S’ 
(‘Synonym’), so that they would all be chosen by MetaMap and SemRep when 
encountered. I then used MetaMap Data File Builder (“MetaMap Data File Builder,” n.d.) 
to compile UMLS files and make them available to SemRep. As an additional step, I also 
removed –D flag from SemRep to identify more concepts. Leaving –D in place would 
block ‘dysonyms’, certain UMLS synonyms that are considered harmful. This version of 
SemRep (henceforth: SemRep_UTH) was used throughout this project for extraction of 
semantic predications and to normalize drug and gene names (explained below). 
SemMedDB_UTH an enhanced repository of semantic predications 
I used 23,537,576 PubMed abstracts downloaded in August of 2014 (henceforth: 
PMAbstracts), as my knowledge source. I processed PMAbstracts (mentioned above) using 
SemRep_UTH, and created SemMedDB_UTH (hosted by the NLM1) (“SemMedDB_UTH 
Database Outline,” n.d.). This database is similar to the original SemMedDB in that it 
follows the same database schema, but contains more predications (especially drugs and 






genes that are important for the purposes of this project), as a result of updated data files. I 
also added a new table, ENTITY, which contained all the concepts recognized by SemRep 
(not just the ones used to create predications). I used the information from the ENTITY 
table to create co-occurrence relationships between drug-gene concept pairs at the 
sentence, and document level. In a similar fashion, I used the ‘summary’ and ‘full 
description’ sections from 183,260 trials downloaded from ClinicaltTrials.gov 
(https://clinicaltrials.gov/) in January of 2015 (henceforth: CTDescs), and added them to 
my data source. I used an original version of  SemMedDB, v. 23 (Kilicoglu et al., 2012; 
Rindflesch et al., 2011; “SemMedDB Info,” n.d.) as the baseline to which I compared my 
results. 
Drug-Gene relations reference set 
To evaluate the results of my queries, I used as the reference set the gene-drug knowledge 
base (henceforth: Gene Sheets) (accessible at http://personalizedcancertherapy.org, with 
permission) provided and maintained by 12 cancer biologists and clinicians at the Sheikh 
Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) Precision 
Oncology Decision Support team at the MD Anderson Cancer Center. Each gene sheet 
contained a list of drugs that are relevant for tumors with alterations in that gene. The Gene 
Sheets describe genetic pathways known to be involved in certain cancer types. Each 
pathway includes a main gene and a list of downstream genes that are thought to be of 
interest as alternative therapeutic targets in the event the main gene cannot be directly 





below), and 17 other genes, ABL1, AKT1, ALK, BRAF, CDK4, CDK6, EGFR, ERBB2, 
FGFR1, FGFR2, FLT3, KDR, KIT, PDGFRA, RET, ROS1, SMO for the summative 
evaluation that followed. All the gene and drug names were normalized to UMLS concept 
unique identifiers (CUIs), or Enterz Gene IDs (for genes only) using SemRep_UTH.  
The Semantic Query 
The semantic query was formulated to represent a query for “drugs that target genes [of 
interest]”. I mapped the verb ‘target’ to different relationship types (predicates) at different 
stages of my project to use in the query. In the preliminary experiment (see below), I chose 
INHIBITS and INTERACTS_WITH to use in the query. The predicate ‘INHIBITS’ was 
chosen because all the genes in the development and test set were oncogenes (rather than 
tumor suppressor genes), and the goal was to find inhibitors of these genes. The predicate 
‘INTERACTS_WITH’ was chosen by examining the existing predications from 
SemMedDB_UTH, observing it tended to represent relationships pertinent to targeted 
therapy. In the final stage of the project (evaluation phase, see below) I added 
COEXISTS_WITH based on the insight gained from tests on a “development set” (see 
below) used to find the optimal set of system parameters. The query would then involve 
finding drugs (output) that were in a certain relationship (predicate) with a known list of 
genes (input). The predicates were all bi-directional (with the exception of INHIBITS), so 
I treated them as such, i.e. I looked for relationships in both directions. I looked for any 
drug that targeted the main gene, any gene downstream, or any of their synonyms. 





the gene synonyms, no normalized form was found by SemRep, and they were excluded 
from the analysis. I limited the query to certain semantic types. For genes, I used gngm, 
aapp, enzy, and for drugs I used orch and phsu in the preliminary experiment, adding antb, 
clnd, horm, imft, nnon, opco, aapp for the final stage of the project. The choice of semantic 
types was made by examining the list of available semantic types in the UMLS (“Semantic 
Types and Groups,” n.d.), and choosing the ones relevant to precision oncology. The choice 
was eventually verified based on the results from the result from the “development phase” 
(See section on “Parameter selection” below). Table 1 shows these semantic types. Figure 
2 shows an overview of the system. 
 
Table 1. Semantic types used to create co-occurrence data 
Semantic Type Description Representing 
aapp Amino Acid, Peptide, or Protein Drugs and genes 
antb Antibiotic Drugs 
clnd Clinical Drug Drugs 
enzy Enzyme Genes 
gngm Gene or Genome Genes 
horm Hormone Drugs 
imft Immunologic Factor Drugs 
nnon Nucleic Acid, Nucleoside, or Nucleotide Drugs 
opco Organophosphorus Compound Drugs 
orch Organic Chemical Drugs 















Figure 2. High level summary of the AIMED system built for finding drugs that target 




The goal of this project was to find clinically-available drugs (i.e., that could be used to 
treat patients). Therefore, I only retained results that were either a drug in clinical trials 
(CT filter) or an FDA-approved drug (FDA filter). I downloaded the list of drugs from 
FDA (http://www.fda.gov/) and normalized them using SemRep_UTH. Also, I processed 
the list of drugs that were mentioned in any ClinicalTrial.gov records and normalized them 
using a similar method. Furthermore, drugs available via clinical trials were associated with 
the trial phase (i.e., phase 1, 1/2, 2, 3, with phase 1/2 involving both phase 1 and 2).(“The 
FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective,” n.d.) For any given drug 
from clinical trials, the highest phase that could be identified was used. FDA-approved 
drugs were assigned phase 4. Using phase information also allowed me to limit the data 
source for the query evaluation. To calculate precision and recall, each drug would be 
considered within its phase category only. For example, to evaluate the query performance 





performance would be calculated against the same phase drugs from the reference set. 
These constraints were motivated by the assumption that the optimal strategy to identify 
drugs in each phase would depend on the number of drugs in this phase and the amount of 
published literature available concerning these drugs. I also used the information from the 
NCI Thesaurus (NCI filter), extracted from UMLS 2013AB, to only keep known 
pharmacologic substances in a systematic fashion. With this filter, I only retained drugs 
that were mentioned under the Pharmacologic Substance branch of the NCI thesaurus, as 
they appeared in the UMLS.  
Preliminary experiment: Comparing SemMedDB to SemMedDB_UTH 
Objective 
To see whether SemMedDB_UTH has any advantage over the standard version of 
SemMedDB in finding drug-gene relationships 
Methods 
For this part of the experiment I chose one gene from the gene sheets (PIK3CA) which 
included two other downstream genes (AKT, MTOR), with seven drugs that would target 
the genes. PIK3CA was chosen as the starting point for the project as it was a current focus 
of IPCT discussion, and a substantial amount of related literature was already available. I 






In total, the number of retrieved drugs were 74 and 35, for SemMedDB_UTH and 
SemMedDB, respectively. SemMedDB_UTH showed a substantial advantage over 
SemMedDB in finding drug-gene pairs for PIK3CA-related genes. (Figure 3), increasing 
precision by two orders of magnitude, and identifying the remaining 70% of the reference 








SemMedDB_UTH showed a clear advantage over the standard version of SemMedDB in 
this experiment. The main difference between the two databases were in the underlying 
ontology that had been used to create them. These findings underline the importance of 





indicated that the changes I introduced to SemRep were in fact effective, and encouraged 
me to continue my experiments. 
Optimization of system parameters  
Objective 
During the development phase of the system, my goal was to find the best strategy for 
utilizing semantic predications and co-occurrence statistics for the task of drug-gene 
relationship extraction in precision oncology. Since the drugs of interest were at different 
development phases, one goal was to find the best set of parameters and constraints that 
would maximize query performance for each phase. I chose four genes as the “development 
set” (see next section) to test the effect of different system parameters on the query 
performance. The results of this development process informed the choice of parameters 
for the evaluation phase.  
Development Set 
The development set consisted of four Gene Sheets (PIK3CA, NRAS, KRAS, MET) chosen 
because they were among the first Gene Sheets developed by the IPCT, and consequently 
were available for development purposes while the remainder of the reference set was 
constructed. The development set also included the downstream genes in their respective 
cancer-related pathways and their known synonyms, as specified in each respective Gene 
Sheet. I used these four genes and their related drugs to find the best set of query parameters 






Table 2 shows a summary of the query parameters and constraints used with the 
development set, as well as the options available for each. 
 
Table 2. Parameters of the system, as applied to query and the answers. 
Parameter Name Description Options 
Semantic 
relationship 
Type of relationship between drug and 
gene required for retrieval. 
Predications, sentence level 
co-occurrence, document 
level co-occurrence 
Food and Drug 
Administration 
(FDA) filter 
Accept drugs that appear on a list of FDA 
approved drugs. The list was obtained 





Accept drugs found in the “intervention” 




Accept drugs either passing the FDA filter 
(marketed) or extracted from 
clinicaltrials.org (CT filter) for trials with 
a phase of at most x (Phases 1-3).  





Return drugs that appear in the 
Pharmacological Substance branch of the 
NCI thesaurus hierarchy.   
Yes/No 
Frequency filter 
Minimum number of extracted 
relationships (predication or co-
occurrence) required before the drug is 
returned. 
One to many (e.g., 5) 
Predication filter 
For predications, retrieve only drugs that 
occur in relationships with the target gene 







Semantic types of drugs to retain. 
aapp, antb, clnd, horm, imft, 












As discussed previously, the drugs that targeted the four genes in this experiment were 
categorized based on their development phases (i.e., clinical trial phase 1, 1/2, 2, 3 and 4 
(FDA-approved)). The phase information was validated using the latest information from 
ClinicalTrials.gov. I considered precision, recall, F1 and F2 measures as my evaluation 
metrics. However, published information about potentially useful drugs may be scarce and 
the annotators expressed a preference for a system that would identify any potentially 
useful drug. Thus, recall was more important than precision, and so, I used the F2 measure 
(a variant of the F measure that emphasizes recall) as the single measure of choice to 
determine the best set of parameters within each drug phase category. The F2 is calculated 
as:  
𝐹2 =
(1 + 22) ∗ 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 ∗ 𝑅𝑒𝑐𝑎𝑙𝑙
(22  ∗ 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛) + 𝑅𝑒𝑐𝑎𝑙𝑙
 
 
Exploration of the space of parameters in Table 2 in an effort to optimize the F2 metric 
yielded the following parameter choices: The optimal data source for marketed (phase 4) 
and phase 3 drugs was the semantic predications alone. This is not unexpected, as one 
would anticipate the availability of more published literature for SemRep processing in 
drugs that have advanced beyond the initial clinical trial stages. For these phases, I included 
results of semantic types pharmaceutical substance (phsu) and organic chemical (orch), 
retaining results for which at least 5 predication instances were found. For phases 2 and 
1/2 I also included sentence level co-occurrence, and for phase 1 I used both predications 





concepts by MetaMap). Note that the set of relationships retrieved on the basis of document 
level co-occurrence subsumes those retrieved using semantic predications, as document 
level co-occurrence is a prerequisite to extraction of a semantic predication. The FDA filter 
for marketed drugs only, CT filter for other drug phases (3, 2, 1 /2, 1), and NCIT filter for 
all phases were also applied. The same set of parameters was used for Experiment 3. Table 
3 shows a summary of the final set of query parameters and constraints. Table 4 shows the 
actual results of the query in the development phase that informed the choice of parameters. 
 
 
Table 3. Optimal system parameters and constraints determined in the development phase. 
Drug Phase Source Frequency Predicates Drug Semantic Type 











2 CoOcc Sen - - complete list 
1 / 2 CoOcc Sen - - complete list  
1 CoOcc Doc - - complete list  
Note: The same configuration was used for evaluation phase. Four Gene Sheets, and 115 
related drugs were included in this experiment, and SemMedDB_UTH was used as the 
source of semantic predications. FDA/CT, and NCI filters were applied to all phases.  















Table 4. Query results with optimal parameters for the development set. 
Drug Phase Documents Drugs Recall Precision F1 F2 
Marketed 624 50 0.86 0.12 0.21 0.39 
3 242 42 0.79 0.26 0.39 0.56 
2 1,466 125 0.69 0.18 0.29 0.44 
1 / 2 993 25 0.45 0.20 0.28 0.36 
1 544 99 0.39 0.20 0.26 0.33 
All phases 3,869 341 0.56 0.19 0.28 0.4 
Note: These results informed the choice of parameters in this experiment. Four Gene 
Sheets, and 115 related drugs were included, and SemMedDB_UTH was used as the 
source of semantic predications.  
Documents: Number of documents returned by the query. Drugs: Number of drugs 





Evaluate system parameters for precision oncology QA 
Objective 
To apply the set of parameters determined in the development phase, on a set of 17 Gene 
Sheets as the “evaluation set”. 
Methods and results 
I used a set of 17 genes (ABL1, AKT1, ALK, BRAF, CDK4, CDK6, EGFR, ERBB2, FGFR1, 
FGFR2, FLT3, KDR, KIT, PDGFRA, RET, ROS1, SMO) as my evaluation set and 
processed them using the optimal parameters determined during system development. The 
gene sheets used in the development phase to identify these parameters were excluded from 
this evaluation.  To establish a baseline, the query was also run on the standard version of 





recall, precision, F1 and F2 (0.39, 0.21, 0.27, 0.33 with SemMedDB_UTH over the 
standard version of SemMedDB at 0.12, 0.05, 0.07, 0.09, respectively) (Table 5). 
 
 







Source Freq. Predicates 
Drug  
ST 



















2,251 80 0.69 0.3 0.42 0.55 











4,723 205 0.5 0.17 0.25 0.36 













1,609 129 0.25 0.19 0.22 0.24 














1,730 661 0.46 0.02 0.04 0.09 





1,730 661 0.17 0.01 0.02 0.04 





1,730 661 0.1 0.01 0.02 0.04 





1,730 661 0.04 0.002 0.004 0.01 





1,730 661 0.01 0.002 0.003 0.01 
All Phases 1,730 661 0.12 0.05 0.07 0.09 
Note: Choice of parameters from each drug phase was determined in the development 
phase. In total 17 Gene Sheets with 276 related drugs were used as the reference set.  
Columns: DB: database used to run the queries; FDA/CT, NCI: filters used to refine the 
results; Freq.: frequency filter; Drug ST: drug semantic types; Doc: number of documents 
returned; Drug: number of concepts returned by the query; Prec: precision; F1: harmonic 







My error analysis focused on false negative results, as annotators had expressed a 
preference for a system with high recall. Of all false negative results (n=168), 19% were 
not found in the original knowledge sources (PMAbstracts, CTDescs). SemRep did not 
identify a CUI for 24%, suggesting that they did not appear in the UMLS data files used to 
extract concepts. Drug filters (CT/FDA, NCI) were responsible for 30% of the false 
negative drugs. Those drugs were either absent from the source vocabularies, or their 
manually designated phases were different from those specified in the filter (e.g., drug that 
was in phase 1 trials at the time that the reference set was created, was in phase 2 trials at 
the time of evaluation). Since all queries were phase based, the phase specified for the drug 
in the reference set had to match the one specified in the CT/FDA filter, or the drug would 
either be found but not matched against the reference set (wrongly marked as false positive 
instead of true positive), or eliminated altogether (false negative); 23% of the missing drugs 
would have been found if I had used a less restrictive approach, i.e., sentence level co-
occurrence instead of predications (for phases 3 and 4), and document rather than sentence 
level co-occurrence. Finally, 4% of marketed drugs were excluded by either the frequency 
or semantic-type filter. 
 
Manual evaluation 
To test the hypothesis that some ostensibly false positive results were actually relevant, 





each drug, experts were provided with a normalized concept name, targeted gene, a random 
selection of up to ten source excerpts of one or more sentences, and a link to the source 
document for each excerpt. To facilitate evaluation, drug and gene names were highlighted. 
For document level co-occurrence results, all sentences from the original document that 
contained the terms in question were provided. Drugs were picked in a stratified random 
manner from a pool of 515 retrieved drugs, equally distributed across the five phase 
categories (i.e., 1, 1/2, 2, 3 and marketed). Each evaluator had 40 unique drugs, and 10 
drugs in common with the other evaluators to assess inter-observer agreement. Thus, a total 
of 135 drugs were evaluated. Each evaluator assigned a score of 1 through 3 to each source 
excerpt (Table 6).  
Of the 135 drugs that were reviewed, 35 (26%) were found to receive score 3, 82 (61%) 
received score 2 and 18 (13%) received score 1. Inter-observer agreement was 100% 
(reviewers 1 and 2), 100% (reviewers 2 and 3) and 60% (reviewers 1 and 3). The drugs 
used to assess inter-rater agreement were different for each reviewer pair. Table 7 shows a 
summary of the distribution of drugs among the reviewers.  
Most of the manually reviewed results were in the score 2 group, which meant that they 
were relevant for review, but the level of evidence did not merit inclusion in the reference 
set (Gene Sheets). The score 2 group was retrospectively divided into three subcategories 







Table 6. The scoring system that evaluator used to score the drug lists 
Score Description 
3 Evidence exists to add to reference set (Gene Sheets). 
Criteria: 
Either:  
 Drug directly targets and inhibits the gene 
OR 
 Drug indirectly targets the gene by inhibiting downstream pathway members  
AND  
there is evidence that alterations in the gene sensitize cells to drugs inhibiting the 
indirect target 
2 Gene name or its alias is mentioned with the drug or its synonym, but evidence is not 




 Indirectly targets the gene but there is no level of evidence for its use in 
tumors with alterations in the gene.   
 Partial response 
 Associated with resistance  
 Effective only in combination 
Low relevance 
 Mutation negative (Patients negative for mutations in a gene were treated with 
a drug) 
 Opposite association (text suggests that the gene target effects the drug, not 
the other way around) 
 Discussing an isoform or artificial version of the gene 
 Derivative of the drug is being discussed (not actual drug indicated in 
evaluation) 
 Association unclear 
 Drug targets molecule upstream of original target (not likely to be effective) 
 No effect 
No relevance 
 Not a drug/not used as a drug 
 No relationship/Effect untested 
 Drug is used as a carcinogen/ would never be used to treat cancer 
 Opposite effect   (The drug results in increased activity of the target gene) 
Not classified 







Table 7. The distribution of drugs among reviewers. 
Drug Count  
(Drug Number) 
Reviewer Agreement Details 
40 (1-40) 1   
40 (41-80) 2    
40 (81-120) 3   
5 (121-125) 1 & 2 5/5 = 100% Both evaluator gave score 2 to all 
the 5 drugs. 
5 (126-130) 1 & 3 3/5 = 60% Both evaluators gave 3 of the drugs 
score 2.  
Evaluator 1 gave one drug score 2 
where evaluator 2 gave it score 3. 
Evaluator 1 gave another drug score 
3, where evaluator 2 gave it score 2. 
5 (131-135) 2 & 3 5/5 = 100% Both evaluators gave score 3 to 3 of 




low relevance, and no relevance), based on curator feedback. Of note, approximately 26% 
of the ostensibly false positive results were in fact relevant for inclusion in the gene sheet. 
If this finding were consistent across the entire evaluation set, the re-estimated precision 
and recall would be 0.29 and 0.55, respectively (versus current 0.21 and 0.39, respectively). 
However, I cannot exclude the possibility that there are other relevant drugs that were 
neither retrieved by the system, nor recognized as such by our team of curators. In this 






At first glance the recall, precision and F2 achieved by AIMED in the evaluation phase are 
relatively modest. However, manual review of ostensibly false positive results showed that 
26% were actually true positives and an additional 61% were appropriate for review, but 
there was insufficient evidence to include these in the reference knowledge base. On the 
one hand this finding shows that the process of maintaining such knowledge bases (which 
is mostly done manually (Griffith et al., 2013; “My Cancer Genome, Genetically Informed 
Cancer Medicine,” n.d.; Percha & Altman, 2015)) can benefit from automated systems. On 
the other hand, it is an indication of how this field is constantly evolving (exemplified by 
the progression of drugs through the development phases during the course of this work) 
and no “gold standard” is likely to be complete, or remain complete for long. The 
performance of a knowledge-based system depends on the accuracy and breadth of the 
source knowledge.(Basili, Hansen, Paggio, Pazienza, & Zanzotto, n.d.; Hristovski et al., 
2015; Lopez et al., 2007) This is consistent with my findings, as I showed that default 
predications from the original SemMedDB were only modestly useful in finding emerging 
medications. Their utility was greatly enhanced by updating SemRep’s source vocabulary, 
and adding predications from other knowledge sources (clinical trials). Further, we 
enriched the underlying ontology by modifying the data files that SemRep was using to 
include suppressed drug names from the NCI thesaurus. Although that technique helped 
with some drug categories, for drugs from lower development phases we had to further 





one could just use co-occurrence, instead of any NLP-derived relationship (i.e. predications 
from SemMedDB_UTH in this case) to find the drugs of interest. My next experiment 
examines this possibility.  
Comparing co-occurrence data with predications 
Objective 
To evaluate the utility of sentence level co-occurrence data for the task of finding drug-
gene relationships of interest. In the previous experiment, I showed that combining 
predications with co-occurrence data can be beneficial, and the utility of each method 
depends on how far advanced the drug is in its development phases. Drug-gene pairs that 
are found in predications are always a subset of sentence level co-occurrence data, and 
since SemRep favors precision over recall. So, a logical assumption might be that using all 
drug/gene co-occurrence data, irrespective of whether a predication was identified or not, 
would result in better recall. In this experiment, I evaluate this hypothesis.  
Methods and results 
For this experiment, I designed two sets of queries. In the first set, only predications were 
used for all the phases, and to maximize the recall for predications, no frequency or 
predicate filters were applied. In the second set, only sentence level co-occurrence was 
used across all the phases. The results are presented in Table 8. Overall, the recall is 0.29 
and 0.44 with predications and co-occurrence respectively, and the precision is 0.13 and 

























Marketed Yes Predications 5046 440 30 5 0.86 0.07 
3 Yes Predications 389 64 18 34 0.35 0.28 
2 Yes Predications 467 91 23 47 0.33 0.25 
1 / 2 Yes Predications 413 12 2 22 0.08 0.17 
1 Yes Predications 129 29 8 87 0.08 0.28 









 Marketed Yes CoOccSen 35706 919 31 4 0.89 0.03 
3 Yes CoOccSen 2614 172 30 22 0.58 0.17 
2 Yes CoOccSen 4723 205 35 35 0.5 0.17 
1 / 2 Yes CoOccSen 3875 40 7 17 0.29 0.18 
1 Yes CoOccSen 1342 97 18 77 0.19 0.19 
All Phases 48260 1433 121 155 0.44 0.08 
Note: Drug filters were applied across both models, and not other filter was used, so that 





SemRep relies on domain knowledge (UMLS) to extract relationships, by applying NLP 
rules at the sentence level.(Rindflesch & Fiszman, 2003) Normally, the recall is expected 
to be higher with co-occurrence than SemRep predications, since the former is not 
restricted by the constraints that the latter imposes on drug-gene pairs. On the other hand, 
since SemRep is optimized for precision, its results are expected to provide higher 
precision than co-occurrence. My results are consistent with both of these expectations. As 
we move from predications to co-occurrence data, a drop in precision, from 0.13 to 0.08 is 





prominent in lower phase drugs than marketed drugs (0.3 for marketed drugs vs. 0.11 for 
phase 1 drugs).  
In the final section of this chapter I will discuss the implications of these finding, and 
explain why they indicate a need for further research in this area.  
Conclusion and next steps  
In this chapter I introduced AIMED system that uses ontology-derived semantic relations 
as well as co-occurrence statistics to find drugs that interact with genes of interest for the 
purpose of supporting precision oncology. I found that relying solely on a knowledge-
driven system (such as the SemRep NLP system (Rindflesch & Fiszman, 2003)) presented 
us with two problems. The first problem involved an underrepresentation of oncology 
drugs in the SemMedDB database (Kilicoglu et al., 2012) due to missing concepts from 
the underlying ontology. To address this issue, I developed SemMedDB_UTH 
(“SemMedDB_UTH Database Outline,” n.d.), which was constructed by modifying the 
vocabulary used by SemRep when extracting knowledge from PubMed abstracts. While 
this improved performance compared to the original edition of the database, I was still 
faced with the second problem, where SemRep did not recognize some of the relationships 
of interest, even when the concepts involved were already identified (SemRep relies on the 
UMLS Semantic Network (At, 1989) to decide which relationships are permissible for any 
given pair of concepts). To address this issue, which was more prominent in cases where 





used co-occurrence statistics to improve performance. However, recall improved, but 
precision decreased, since results were no longer constrained by the underlying ontology.  
These experiments revealed an underexplored area between the linguistic rules and 
semantic constraints that systems such as SemRep impose on the one hand (thus achieving 
higher precision), and the unconstrained relationships defined by co-occurrence (evident 
by higher recall) on the other. Absence of predefined relationship types to constrain 
Boolean retrieval can lead to overwhelmingly large result sets. The question arises as to 
whether other mechanisms than semantic predications (or NLP-based sentence-level 
relationship extraction in general) might be used to constrain the large numbers of 
drug/gene co-occurrence instances detectable in the literature to identify drugs of interest.  
In the following chapter I evaluate the extent to which methods of distributional semantics 











Chapter 4: Comparing models of attributional and relational similarity for recovery 
of held-out drug/gene relationships 
In the previous chapter, I introduced AIMED, a QA system that tries to find relevant drug-
gene relationships for precision oncology, by using knowledge-based NLP methods and 
unconstrained co-occurrence information. I showed that NLP methods, which depend on 
established knowledge, have limited coverage in rapidly evolving domains such as 
precision oncology, and in particular with drugs in lower development phases (evident by 
low recall). On the other hand, using co-occurrence as a means to find relationships in an 
unconstrained fashion, presents us with a different problem, as the number of results 
returned by the system can be too large to be useful (low precision). One potential solution 
involves statistical systems that neither rely on explicit assertions (co-occurrence), nor are 
limited to pre-defined relationship types (such as “INHIBITS” in the case of knowledge-
based predications), and reason on the basis of similarity. In this chapter I explore the utility 
of a corpus-based approach to this problem, by applying a range of relational and 
attributional similarity methods, in the framework of the specific aims for my dissertation. 
Much of the material presented in this chapter is borrowed from a manuscript under review 






According to the “distributional hypothesis” in linguistics (Harris, 1954) words that occur 
in similar contexts are likely to have similar meanings. Methods of distributional semantics 
derive similar representations for terms that occur in similar contexts in the 
literature.(Trevor Cohen & Widdows, 2009) Thus, two drugs that exist in similar contexts 
(e.g. a document, or a sliding window) may be similar in some respects.  Attributional 
similarity concerns the similarity between entities (such as two drugs) (Medin et al., 1990), 
which with distributional methods is estimated based on the contexts in which they occur 
across a large corpus. (Landauer & Dumais, 1997; Turney, 1997) In contrast, relational 
similarity concerns the similarity between pairs of entities (such as two drug-gene pairs) 
(Turney & Littman, 2005), and with distributional methods is estimated from the contexts 
in which these entity pairs occur together (see for example (Turney, 2005)). While it seems 
intuitive that relational similarity could help to identify relationships of interest between 
biomedical concepts, little was understood about the relative merits of relational and 
attributional similarity as a means to accomplish this task at the outset of this doctoral work. 
To address this gap in the literature, the work described in this chapter involves an 
evaluation of the relative utility of relational and attributional similarity for a task of this 
nature. Specifically, I compare the performance of multiple relational and attributional 
similarity methods on the task of identifying drugs that may be therapeutically useful in 
the context of particular molecular aberrations, compared to a gold standard (“the reference 





seeds and apply similarity measures to find target drugs in the search space. My hypothesis 
is that relational similarity will be more effective than attributional similarity when applied 
to this task. 
In the sections that follow I will describe the steps that I took to evaluate this hypothesis. I 
will provide a brief account of the construction of the search space for target drugs, 
followed by a description of the reference set, and detailed account of the methods used to 
estimate attributional and relational similarity.  
Search space (“Training Corpus”) 
I used Medline abstracts as the source of information for all similarity models in this 
evaluation. Specifically, I used additional components of SemMedDB_UTH 2015 
(Fathiamini et al., 2016; “SemMedDB_UTH Database Outline,” n.d.) (introduced in 
chapter 3), which provides all the sentences (144M) extracted from 23.4M Medline 
abstracts dated up to Sep 2014, as well as a list of the UMLS and EntrezGene concepts 
found in each sentence, their semantic types, and CUIs. I replaced the narrative descriptions 
of all concepts extracted by MetaMap from the abstracts with their CUIs, and removed stop 
words using the stopword list from the SMART information retrieval system. (Salton, 
1971) For example, “Sialyl-Tn antigen expression was studied immunohistochemically in 
211 primary advanced gastric carcinomas.” was transformed to 
“C0074480 C0185117 studied C1441616 211 C1335475”. I will refer to text so 
transformed as CUI-transplanted text for the remainder of the chapter. The result of this 





retained in an Apache Lucene index (“Apache Lucene,” n.d.) to facilitate search and 
retrieval. To extract explicit drug-gene pairs and their intervening terms, I further processed 
individual sentences from the CUI-transplanted abstracts, and whenever a drug co-occurred 
with a gene in a sentence I extracted the words that lay between them. In this fashion, I 
identified 52,465,681 drug-gene pair co-occurrence events, and combining their 
intervening terms (including other CUIs and non-CUI terms) resulted in representations 
for 6,899,439 unique pairs, each with a “bag of words” (BOW) consisting of every term 
that occurred between their constituent CUIs in any sentence in the corpus. 
Search Space Filters  
Methods of distributional semantics produce continuous estimates of relatedness between 
entities, and as such, they are well suited toward rank-ordering vectors within a search 
space of potentially therapeutic agents. To construct this search space I removed from the 
list of extracted concepts any entity that was neither a gene nor a drug. I retained only  
concepts with UMLS semantic types aapp, antb, clnd, horm, imft, nnon, opco, orch, phsu 
for drugs, and aapp, enzy, gngm for genes (aapp was used for both drugs and genes), 
informed by results produced by different configurations of AIMED (Fathiamini et al., 
2016). Next, since the goal of the system was to find clinically relevant drugs, I used 
several filters, developed during the course of the AIMED project, to eliminate concepts 
that met the semantic type constraints, but were not clinically applicable.  Specifically, the 
NCI drug filter only includes drugs that are mentioned in the NCI terminology as a 





database, and the FDA filter includes only FDA approved drugs. The retrieved entries had 
to exist in either the FDA or CT list, and the NCI filter to pass the drug filter. To ensure 
that the performance of pair and entity-based models was compared across the same search 
space, only drugs and genes that had representatives in both the entity-based and pair-based 
spaces were retained. To meet this last constraint, a drug would need to co-occur at least 
once with the gene in question. Figure 4 shows a high-level data flow diagram providing 




Figure 4. High level data flow diagram from Medline abstracts to different models. 
Note: RI=Random Indexing. CUI-transplanted Medline abstracts were used to create entity and 
pair representations. The drug filters were applied, and only concepts that had representatives in 
both spaces were retained. The open source Semantic Vectors package (see below) was used to 
create different vector models: RI Attributional (see below), RI Relational (see below), 
Embeddings Relational (see below), and Embeddings Attributional (see below). Two other models, 







The reference set 
As a reference set to test the system output and validate the results, I used the knowledge 
base provided and maintained by cancer biologists and clinicians at the Precision Oncology 
Decision Support (PODS) team at the MD Anderson Cancer Center, Sheikh Khalifa Bin 
Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), accessible with 
permission at http://personalizedcancertherapy.org. Each gene and its associated drugs 
(collectively known as a Gene Sheet – GS) included in this knowledgebase was deemed by 
the PODS team to have treatment implications for certain cancer types. To build upon my 
findings from AIMED, I used the same Gene Sheets from the “evaluation set” of AIMED 
to test my hypothesis. This list included 17 genes (and some of their 
synonyms/CUI/Entrez_ID variations), and 430 drugs known to target them (and 1035 
synonyms/CUI variations).  
All the entries in this reference set were normalized to UMLS CUIs or EntrezGene IDs for 
genes, henceforth collectively referred to as CUIs in this chapter for uniformity, by 
SemRep_UTH. Some of the drugs were excluded from the evaluation, either because they 
were not identified as ‘drug’ by SemRep_UTH; or because they were not found in the drug 
filters (explained above). Also, following the practice explained in (Chiu, Crichton, 
Korhonen, & Pyysalo, 2016), if a drug had no representation in the search space, I 
systematically disregarded it in the evaluation. This resulted in the GS for one gene (KIT) 
being removed from the reference set, as all its drugs were eliminated in the filtering 





a list of the genes used for this purpose, and the number of therapeutically-relevant drugs 
for each of them with representation in my entity-based vector spaces before and after 
imposition of the constraint that only drugs co-occurring with genes in a CUI-transplanted 
sentence at least once were included in the evaluation. That is to say, the current 
experiments, only drugs that met the co-occurrence constraint after filtering (bottom row 
of Table 9) were considered as positive examples. This co-occurrence constraint is a 
prerequisite to comparison between pair- and entity-based methods. However, it greatly 
constrains the number of drugs under consideration, a limitation I will subsequently 
discuss. This reduction in the number of therapeutically relevant drugs that could be 
considered for my experiments with the imposition of the co-occurrence constraint had a 
corresponding effect on the number of drugs remaining in the search space, reducing a total 
of 3,256 represented drugs (after filtering) to 1,144. The proportion of drugs that were 
therapeutically relevant in at least one context was similar before (.073) and after (.087) 
this filtering.  
Many drugs that met the constraints for inclusion in the resulting reference set were shared 
among two or more genes. That is to say, they were considered to be therapeutically active 
in the presence of an aberration to multiple genes. Out of the 16 genes in this set, five had 
all their drugs shared with other genes, and only one gene (SMO, targeted by only one 
drug) shared no drug with the others. Figure 5 shows a summary of the drug overlap 
between any given gene and the rest of the genes. An important implication of this overlap 





times, include positive examples from the held-out gene sheet used at a particular point in 
the cross-validation procedure.  
 




































































































Number of therapeutically 
relevant drugs (TRD) 
17 43 5 24 14 7 41 53 29 19 30 53 32 16 3 8 394 237 
TRD found in entity-based spaces  
(ri_att, emb_att, emb_rel, rand-
vec)* 
11 23 3 10 4 3 22 26 15 10 19 33 24 11 2 1 217 118 
TRD-gene pairs found in pair-
based  
spaces (ri_rel, frequency)* 
9 21 2 10 4 3 20 20 14 10 7 25 12 3 2 1 163 99 
Note: There are fewer representations of drug-gene pairs than there are of therapeutically 
relevant drugs, as some therapeutically-relevant drugs did not co-occur with the gene in 
question, prohibiting the generation of a drug-gene pair representation. Sum: total 
number of therapeutically-relevant drug/gene pairs. Total unique drugs: total number of 
drugs that were considered therapeutically relevant in at least one context. 










Search and Evaluation Process 
I used known examples from the reference set as seeds and applied similarity measures to 
find target drugs in the search space, and the results were compared against the reference 
set. Based on the observation that in biomedicine there is often more than one correct 
answer to any given analogy question (Newman-Griffis, Lai, & Fosler-Lussier, 2017), and 
since distributional methods aim to prioritize results based on a continuous measure of 
similarity, I used standard ranked retrieval metrics to evaluate the results. The Average 





where  n = number of results returned 
IsRelevant   = 1 for therapeutically-relevant drugs, otherwise 0 
TR   = total number of relevant answers (whether they are returned or not) 
P(k)   = precision at the point at which the kth result was returned. 
I also calculated Mean Average Precision (MAP) as the arithmetic mean of the AP values. 
The details and scope of the models involved in these evaluations are presented in 
subsequent sections.  
Aim 1: Develop and implement models of attributional and relational similarity 
In Aim 1, I built models of attributional and relational similarity to test my hypothesis. I 





techniques (Mikolov, Chen, et al., 2013; Mikolov, Sutskever, Chen, Corrado, & Dean, 
2013) to build my vector spaces. These operations were performed using the open source 
Semantic Vectors package2 (Widdows & Cohen, n.d.; Widdows & Ferraro, 2008) which 
provides implementations of both of these approaches, eliminating the possibility of 
introducing bias on account of differences in pre-processing and tokenization of text 
(semanticvectors, n.d.; Widdows & Cohen, n.d.; Widdows & Ferraro, 2008). 
Relational similarity models 
I used two approaches to model relational information. In the first, I explicitly identified 
drug-gene pairs, and created vector representations for them based on the terms that lie 
between them when they co-occur in my corpus of CUI-transplanted abstracts. Relational 
similarity was estimated based on the similarity between these pair vectors. A disadvantage 
of this approach is that all drug-gene pairs must be identified beforehand.  
In contrast, in the second approach, I used the implicit relational information captured 
during the course of generating neural word embeddings, and performed geometric 
operations on the resulting concept vectors (𝐷𝑟𝑢𝑔𝑐𝑢𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ − 𝐺𝑒𝑛𝑒𝑐𝑢𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  + 𝐺𝑒𝑛𝑒𝑡𝑎𝑟𝑔𝑒𝑡⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ≅ ?, as in 
the example 𝑃𝑎𝑟𝑖𝑠⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ − 𝐹𝑟𝑎𝑛𝑐𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ + 𝐼𝑡𝑎𝑙𝑦⃗⃗⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ≅  𝑅𝑜𝑚𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗) (Mikolov, Chen, et al., 2013). Relational 
similarity was estimated as the cosine metric between the vector resulting from these 






arithmetic operations and the vector for each drug in the search space (as this will be high 
if  𝐷𝑟𝑢𝑔𝑐𝑢𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ − 𝐺𝑒𝑛𝑒𝑐𝑢𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ≅  𝐷𝑟𝑢𝑔𝑡𝑎𝑟𝑔𝑒𝑡⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ − 𝐺𝑒𝑛𝑒𝑡𝑎𝑟𝑔𝑒𝑡⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ). 
Attributional similarity 
To model attributional information, I used CUI-transplanted abstracts as documents to 
build vector spaces, and measured the cosine similarity between concepts. Drugs known to 
be effective against particular genes were used as seeds to find other drugs by assessing 
their cosine similarity. In my first approach, I used Random Indexing to build the vector 
space, and the second approach I used the same neural concept embeddings space from the 
relational similarity experiment, but instead of using relationships, individual drugs were 
used as seeds to find similar drugs.  
Preliminary Experiments and Parameter Selection  
Each of the methods introduced above can be executed using different sets of parameters 
that could affect performance. Preliminary experiments were performed to choose the 
optimal set of parameters for each model. All models used a minimum word frequency of 
10. The vector dimensionality was 1000 for RI-based models (which tend to require 
relatively high dimensionality), and 500 for neural embedding models (which have been 
shown to perform well at relatively low dimensionalities).  
Attributional similarity with Random Indexing (ri_att-RI) 
In my first approach, I built a simple Random Indexing (M. Sahlgren, 2005) space. A set 





vectors of dimensionality 1000 and randomly assigning 10 of these values to either +1 or -
1. The result is a set of document vectors with a high probability of being orthogonal, or 
close-to-orthogonal, on account of the statistical properties of high-dimensional space (M. 
Sahlgren, 2005). Term vectors were built by adding together the document vectors they 
occurred in. This process can be expressed as:  
 ?⃗?
 = ∑ 𝑟𝑎𝑛𝑑𝑉𝑒𝑐(𝐷)
(𝑡)∈𝐷
  
where ?⃗?  represents the term vector, D is a given document, t denotes a given term in the 
document, and randVec is the function to assign random vectors to documents. 
 Attributional similarity with Reflective Random Indexing (ri_att-RRI) 
In this approach, a Term-based Reflective Random Indexing (TRRI) (Trevor Cohen, 
Schvaneveldt, & Widdows, 2010) space was built. In TRRI, random vectors are assigned 
to terms (a combination of terms and CUIs in my case), and added together to generate 
document vectors for documents containing those terms, which are subsequently 
normalized. Log entropy was used as the term-weighting scheme. This is the beginning of 
an iterative training procedure – new term vectors are generated by adding together the 
document vectors for documents in which they occur in, then the cycle can be repeated if 
necessary. This provides a computationally convenient way of estimating the relatedness 
between terms that do not co-occur directly together in documents, as terms that co-occur 
with similar other terms will also have similar vectors. The process can be expressed as the 






1. ?⃗? = ∑ 𝑟𝑎𝑛𝑑𝑉𝑒𝑐(𝐿𝐸(𝑡))(𝑡)∈𝐷  










where ?⃗?  represents the document vector, D is the set of terms in each document, t denotes 
a given term in the document, randVec is the function to assign random vectors to terms, 
LE is the log entropy term weighting function, and ?⃗?  is the final term vector. Ri_att-
RRI was built with the same dimensionality and number of random values as the 
previously discussed ri_att-RI space, over a single iteration (random term vectors  
document vectors  term vectors). 
Relational similarity with pair vectors and Random Indexing (ri_rel-RI) 
As a relational counterpart to ri_att-RI above, I created vector representations of 
drug/gene pairs in accordance with the RI paradigm (Kanerva et al., 2000). I treated each 
distinct BOW (see above) as a pseudo-document, generating pair vectors by adding 
together the random vectors for the terms in each BOW and normalizing the result. No 
term weighting scheme was used. This process can be expressed as:  
 ?⃗?







where ?⃗?  represents the pair (pseudo-document) vector, P is the set of terms in each BOW, 
t denotes a given term in the BOW, and randVec is the function to assign random vectors 
to terms.  
Relational similarity with pair vectors and Reflective Random Indexing 
(ri_rel-RRI) 
This model was similar to ri_rel-RI in that I treated each distinct BOW as a pseudo-
document, and created pair vectors by adding together vectors for terms in each BOW and 
normalizing the result. The difference, however, was that instead of using random vectors 
for terms, I used the term vectors trained in the process of TRRI for ri_att-RRI model 
explained above. I hypothesized that doing so would provide the means to assess the 
similarity between pair-based pseudo-documents containing semantically related but non-
identical terms. The process of generating pair vector representations can be expressed as:  
 ?⃗?
 = ∑ 𝑟𝑒𝑡_𝑎𝑡𝑡𝑟𝑖𝑏_𝑅𝑅𝐼(𝑡)
(𝑡)∈𝑃
  
where ?⃗?  represents the pair (document) vector, P is the set of terms in each BOW, t denotes 
a given term in the BOW, and ret_attrib_RRI is the function responsible for retrieving term 
vectors from the ri_att-RRI space.  
Relational similarity with concept embeddings (emb_rel) 
A second class of relational models were built using the Semantic Vectors implementation 





provided in (Mikolov, Chen, et al., 2013; Mikolov, Sutskever, et al., 2013) for word 
embeddings, with the source abstracts (rather than sentences) as documents. With SGNS, 
a neural network is trained to predict the terms surrounding an observed term, within a 
sliding window that is moved through the text. The probability of a surrounding term given 
an observed term is estimated as the sigmoid function of the scalar product between the 
input weights of the observed term, and the output weights of the surrounding term. The 
network is trained using stochastic gradient descent to optimize the following objective: 
 ∑ log𝜎(𝐼(to). 𝑂(tc)) 
(𝑡𝑜,𝑡𝑐)∈𝐷
+ ∑ log 𝜎(−𝐼(to). 𝑂(t¬c)) 
(𝑡𝑜,𝑡¬𝑐)∈𝐷ʹ
  
where D is a set of observed terms (to) and their context terms (tc), D’ is a set of observed 
terms (to) and corresponding randomly drawn terms (tc) that are unlikely to occur in the 
context of the observed terms. I denotes the input weights for each term, O denotes the 
output weights for each term, and  is the sigmoid function, which converts the scalar 
product of the input and output weights concerned into a value between 0 and 1 that can be 
interpreted probabilistically. Optimization of this objective results in high predicted 
probabilities for terms that occur in the context of an observed term, and low predicted 
probabilities for terms that do not. The input weights (I) are retained as the word (or 
concept) embeddings, although it has been shown that retaining the output weights (O) is 
advantageous in some experimental settings (Levy et al., 2015). Neural embeddings have 
been shown to capture a form of implicit relational similarity, which can be used to solve 





al., 2013), using simple geometric operations. With this model, assuming drug1 has a 
similar effect on gene1 to drug2’s effect on gene2, an equation can be established such 
that, assuming relational information is captured accurately: 𝑑𝑟𝑢𝑔1⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ − 𝑔𝑒𝑛𝑒1⃗⃗⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ ≅ 𝑑𝑟𝑢𝑔2⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ −
𝑔𝑒𝑛𝑒2⃗⃗⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗. In my example, drug1 and gene1 are in a known relationship with each other, and 
the goal is to find drug2 in relationship with the gene of interest, gene2. As such, drug2 
can be found using this equation: 
 𝑑𝑟𝑢𝑔2⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ ≅ 𝑑𝑟𝑢𝑔1⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ − 𝑔𝑒𝑛𝑒1⃗⃗⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ + 𝑔𝑒𝑛𝑒2⃗⃗⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗  
Attributional similarity with concept embeddings (emb_att) 
In this experiment, I used the same word embeddings space as the previous model to find 
drugs similar to known drugs from the reference set.  
Parameter variations with embeddings models 
Prior work has evaluated the effect of neural word embedding hyper-parameters on task 
performance in the biomedical domain (Chiu et al., 2016; Levy et al., 2015). I assessed two 
of those parameters: subsampling (ss: the process of ignoring instances of frequently 
occurring terms with some probability – I used 1 − √(𝑇/𝐹)  as described in (Mikolov, 
Sutskever, et al., 2013), where T is a threshold, and F is the number of times a term occurs 
in the corpus divided by the total number of terms in the corpus) at thresholds of 10-3 and 
10-5, and window size (ws: the number of words considered before and after the target 
word, in the context of a sliding window) at levels 5 and 8. Furthermore, based on the 





vectors (w+c) with SGNS could help improve performance on pairwise analogy tasks, I 
tested models with and without context vectors. Overall, six versions of the embeddings 
search space were built using different combinations of these parameters, as summarized 
in Table 10. 
Baseline models 
To establish a baseline and to assess the effect of co-occurrence alone without any 
similarity measure, the original drug-gene pairs that were identified in the course of 
building the ri_rel models were sorted based on their frequency of co-occurrence across 
the entire search space. In this model (henceforth: “frequency” model), the more a drug 
co-occurred with a gene, the higher it ranked. For each gene of interest, the resulting ranked 
list of drugs was compared with the reference set for evaluation.  
A second baseline model was built using a set of random vectors for individual concepts 
(henceforth: “rand-vec” model). In a manner similar to the attributional methods 
described above, drug vectors were used to find similar drugs, and the results were 
compared with the reference set for evaluation. The intuition here was since the vectors 
used in this model were randomly chosen, they have a high probability of being orthogonal 
or close-to-orthogonal to each other. Consequently, any performance observed must occur 
on account of random overlap between vectors (as they are not perfectly orthogonal), or 
because drugs overlap across reference sets (as discussed above). Thus, inclusion of the 





exceeds that produced by incidental overlap. Table 10 summarizes different models, and 
their variants, used for search.  
 
 
Table 10. Similarity models used for search. 













 ri_att: Abstracts as documents, 
cosine similarity measured 
between term vectors 
- ri_att-RI: term vectors sum of 
random document vectors (RI) 
- ri_att-RRI: term vectors sum of 
document vectors trained on random 
term vectors (TRRI)  
ri_rel: Drug-gene pairs-based BOW as 
document, cosine similarity measured 
between pair (document) vectors 
- ri_rel-RI: document vectors sum of random 
term vectors (RI) 
- ri_rel-RRI: document vectors sum of term 












emb_att: Abstracts as 
documents, cosine similarity 
measured between term vectors 
 
- emb_att-001_ws5: ss=10-3, ws=5 
- emb_att-001_ws8: ss=10-3, ws=8  
- emb_att-00001_ws8: ss=10-5, 
ws=8 
 
All three variations above with 
w+c 
- emb_att-001_ws5_w+c 
- emb_att-001_ws8_w+c  
- emb_att-00001_ws8_w+c   
emb_rel: Abstracts as documents, cosine 
similarity measured after geometric 
operations on term vectors:  
𝐶𝑢𝑒 𝐷𝑟𝑢𝑔⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗   − 𝐶𝑢𝑒 𝐺𝑒𝑛𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  + 𝑇𝑎𝑟𝑔𝑒𝑡 𝐺𝑒𝑛𝑒⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗  ⃗ =  ? 
 
- emb_rel-001_ws5: ss=10-3, ws=5 
- emb_rel-001_ws8: ss=10-3, ws=8  
- emb_rel-00001_ws8: ss=10-5, ws=8 
 
All three variations above with w+c   
- emb_rel-001_ws5_w+c 







e  frequency: drug-gene pairs sorted by the number of occurrence in the 
abstracts, search by gene returned drugs 
 rand-vec: Abstracts as documents, cosine similarity measured between 






Aim 2: Recovery of held-out drug/gene relationships 
In this phase, I evaluated the models from Aim 1 for their ability to recover held-out drugs 
and drug-gene pairs by using a set of seeds examples from the reference set (introduced 
previously), across a range of cross-validation configurations. 
Cross-validation configurations 
As explained previously, both relational and attributional models require seed examples, 
so that ranked retrieval of target entries can occur based on similarity to these seeds. For 
attributional models the seed and target were drugs, and for relational models they were 
drug-gene pairs. With the frequency model the “seed” was just the gene in question, 
and I ranked the drugs that co-occurred with it based on frequency. To evaluate the pair-
based models, rankings of retrieved pairs containing the reference set drugs were 
considered. For the sake of uniformity, I will refer to pair-based seeds and targets, simply 
as “drugs”. I conducted my evaluation both at a single GS level (InGene – all cues and 
targets directly concerned the gene of interest), and across all the GSs (ExGene – the gene 
of interest served as the target, where all the other genes were used as seeds). My hypothesis 
was that the InGene configuration would elicit the best performance from attributional 
models (as retrieved drugs would be similar to drugs that are known to be effective), while 
the ExGene configuration would elicit best performance from relational models (as the 
nature of the relationship between therapeutically relevant drugs and the genes they target 





InGene models  
In the InGene model the scope of the cross validation was limited to one single GS at a 
time (given knowledge of some drugs known to affect this gene, can I find others?) I used 
two cross validation strategies. Both strategies are forms of leave-one-out cross-validation, 
but they differ with respect to the number of drugs that are retained as seeds. With the first 
strategy, known as One-As-Seed (“oas”), I took one “target” drug at a time from the 
reference set and used all the other drugs individually as seeds to find it and calculate AP. 
Of note, since there was only one target drug to find, the AP was equivalent to reciprocal 
rank in this case. MAP for each gene was calculated by averaging the set of AP results (or 
rather, reciprocal ranks) obtained in this process. For t target drugs and s seed drugs, the 
number of reciprocal ranks averaged is t*s. The utility of each possible seed for retrieval 
of each target is evaluated. The second strategy, known as All-But-One (“abo”), involved 
using all the drugs (with vectors combined) to find a single held out drug. In this model the 
cue was the normalized superposition of the vector representations of all the cues 
concerned. For each gene, MAP was then calculated across this set of AP results (or more 
accurately, reciprocal ranks) (one for each held-out drug). Irrespective of the number of 
seed drugs, this average was calculated over t reciprocal rank results. As such, the main 
difference between “oas” and “abo” was that in the former, seed drugs were used 
individually to find the target drug with the results averaged later, whereas in the latter, a 
cumulative seed vector was used as a cue. The motivation for this design was that in 





results (as in the case where annotators have yet to begin constructing a gene sheet), and 
building the basis for further discoveries – hence the oas model. On the other hand, when 
information is already available (as in the case of an existing gene sheet that needs to be 
maintained as new potentially useful drugs are described in the literature), one would try 
to maximize the robustness of the query vector by including in it as many existing positive 
answers as possible – hence the abo model. It has been shown that combining multiple 
examples as cues lead to better performance on analogical reasoning experiments. (Trevor 
Cohen et al., 2011; Drozd, Gladkova, & Matsuoka, 2016) As such, my hypothesis was that 
in any given class of experiments, the abo models would perform better than oas.  
ExGene models 
In the case of ExGene model (given knowledge of drugs known to affect other genes, can 
I find those affecting this one?), the oas model was implemented by first adding (and 
normalizing) the vectors for individual drugs under each seed gene to form one prototypical 
drug vector for each GS (one gene sheet as seed), and then using that vector to find the 
drugs that target the target gene. Consequently, with t target drugs for a gene sheet, and g 
other gene sheets, the MAP was calculated by averaging across g average precision results. 
With ExGene, the abo model simply involved adding up the vectors for all the drugs under 
all the seed genes (and normalizing them afterwards) to use as the seed. Consequently, with 
t target drugs for a gene sheet, the MAP simply equaled the average precision, which was 
calculated only once per target gene, irrespective of the number of other gene sheets or t. 





described in Table 10 with these cross-validation configurations, and report the median of 
MAP values for the genes in the reference set.  Also, as explained previously, many genes 
in the reference set had drugs that were also mentioned in other Gene Sheets. I hypothesized 
that this drug overlap would affect the MAP results for ExGene models, since for those 
genes, seed and target sets have drugs in common. Positive correlation between model 
performance and the degree of drug overlap may explain the results. To this end, I ran a 
Spearman Rank Order test to evaluate the correlation between degree of drug overlap 
among genes in the reference set, and the MAP results for each gene-model combination.  
Final Filtering of Result 
In all of the evaluations explained above, a drug-gene co-occurrence filter was applied to 
each result set from entity-based models, before calculating the AP. For each such model, 
drugs that did not co-occur with the gene in question in at least one original source sentence 
were eliminated, so that entity and pair-based models could be compared against the same 
set of constraints.  
 
Results 
I ran some preliminary experiments to determine the best set of hyperparameters for the 
models. A summary of the net effect of those hyperparameters on model performance is 
presented in Table 11. Based on these findings, I chose the following model configurations 
as the representatives in their respective categories: ri_att-RRI for attributional RI, 






Figure 6. Diagram of different cross validation models. 
Note: 1) oas-InGene: Drugs in a Gene Sheet are used individually to find a target drug, 2) 
abo-InGene: Drugs in a Gene Sheet are combined (vectors superimposed, normalized), and 
used to find a target drug, 3) oas-ExGene: Gene Sheets are used individually (with drugs 
within each combined), to find drugs in a target Gene Sheet, 4) abo-ExGene: Gene Sheets 
are used in combination (all their drug vectors combined) to find drugs in a target Gene 
Sheet. In oas models, results from individual queries are averaged (shown as “(avg)” on 
the diagram) and reported as AP for the target drug(s). 
 
 
emb_rel-00001_ws8_w+c for relational embeddings.  
As shown in Table 12 below, the best performing model overall was emb_rel abo-







Table 11. Effect of different hyperparameters on model performance. 
Hyperparameter emb_rel emb_att ri_rel ri_att 







Subsampling threshold  
from 0.001 to 0.00001 
increase - 
21% 
decrease - 3% n/a n/a 




decrease - 2% n/a n/a 
Replacing RI with RRI n/a n/a decrease - 
23% 
increase - 250% 
Note: Average increase/decrease is shown for each model across different configurations 
(abo/oas, InGene/ExGene). Adding context to word vectors consistently improved 
performance across embedding models, a finding shown in boldface. Some of the 





abo_InGene. Across RI-based models, ri_rel outperformed ri_att in the ExGene 
configurations, but not in the InGene categories. With embeddings-based models, 
emb_rel performed better than emb_att in ExGene models (emb_rel is not defined 
with InGene). Finally, the abo configurations were associated with better performance than 
oas in all models, with only one exception, ri_att oas-ExGene. The results of the 
correlation test that I performed to assess a potential link between some of the results, and 
the degree of drug overlap in the Gene Sheets are presented in Table 13.   
A brief review of the practical utility of the methods 
As discussed previously, a substantial proportion of therapeutically relevant drugs were 
eliminated to facilitate comparison with pair-based models. To better estimate the practical 





Table 12. MAP per gene-model combination, and the median MAP per gene. 








































































































 oas-InGene 0.10 0.12 0.04 0.38 0.12 0.01 0.03 0.09 0.05 0.10 0.11 0.15 0.05 0.17 0.14 1.00 0.00 
abo-InGene 0.30 0.38 0.06 0.75 0.31 0.01 0.05 0.33 0.25 0.31 0.21 0.30 0.35 0.75 0.28 1.00 0.00 
oas-ExGene 0.34 0.37 0.12 0.63 0.40 0.18 0.29 0.34 0.33 0.36 0.28 0.32 0.29 0.38 0.33 0.66 0.74 









oas-ExGene 0.72 0.71 0.38 1.00 0.83 0.64 0.74 0.65 0.67 0.42 0.53 0.34 0.93 0.92 0.73 0.93 1.00 

















 oas-InGene 0.16 0.20 0.09 0.53 0.23 0.27 0.38 0.11 0.09 0.09 0.14 0.14 0.08 0.20 0.52 0.17 0.00 
abo-InGene 0.46 0.69 0.31 0.75 0.68 0.47 0.55 0.47 0.32 0.17 0.27 0.45 0.25 0.58 0.78 0.17 0.00 
oas-ExGene 0.16 0.20 0.09 0.10 0.12 0.09 0.10 0.12 0.15 0.28 0.31 0.32 0.36 0.49 0.55 0.17 0.03 








 oas-InGene 0.18 0.20 0.07 0.49 0.20 0.20 0.21 0.09 0.08 0.11 0.16 0.15 0.14 0.25 0.50 0.67 0.00 
abo-InGene 0.23 0.47 0.15 0.38 0.60 0.21 0.24 0.20 0.12 0.18 0.22 0.20 0.55 0.83 0.56 0.67 0.00 
oas-ExGene 0.40 0.32 0.12 0.28 0.51 0.40 0.32 0.24 0.28 0.39 0.42 0.36 0.87 0.94 0.58 0.75 0.58 
















 oas-InGene 0.02 0.02 0.01 0.03 0.04 0.01 0.00 0.01 0.02 0.02 0.04 0.03 0.03 0.12 0.14 0.00 0.00 
abo-InGene 0.02 0.02 0.01 0.02 0.02 0.01 0.01 0.02 0.01 0.02 0.04 0.01 0.07 0.23 0.28 0.00 0.00 
oas-ExGene 0.15 0.18 0.03 0.12 0.12 0.07 0.08 0.06 0.08 0.23 0.26 0.24 0.27 0.39 0.49 0.19 0.03 
abo-ExGene 0.27 0.45 0.03 0.21 0.23 0.18 0.14 0.06 0.09 0.69 0.59 0.73 0.60 0.73 1.00 0.31 0.03 
*Included reference drugs 9 21 2 10 4 3 20 20 14 10 7 25 12 3 2 1 
†Drugs with vector 
representations 
3,256 
‡Drugs co-occurring with genes 213 797 50 231 160 183 501 302 295 141 240 177 54 24 33 76 
Note: Best results for each attributional or relational method are underlined, and best 
result for each gene sheet and overall are shown in boldface.  
*Number of drugs in the reference set copied from Table 9.   
†Drugs in the vector space after applying filters explained earlier in the text.  
‡ Number of drugs available for search per gene concerned. The co-occurrence constraint 
explained earlier effectively reduced the number of drugs available for search from 3,256 
to 1,144 unique drugs, with an average of 217 available for consideration for each gene 






attributional categories with the full set of available drugs in the reference set (394 
therapeutic applications for drugs across 16 Gene Sheets, Table 9) with all the other 
constraints the same as the main experiment, and found the median MAP to drop an average 
of 0.26 across those representative models (Table 14). In doing so, I am penalizing the 
models for not finding drugs that are not represented in the vector space, placing a hard 
ceiling on performance. It is notable that in this case, the relational models still 




Table 13. Spearman Rank-Order Correlation Coefficient values 
































































































Overlap/MAP Correlation -0.4 -0.39 -0.32 -0.25 -0.03 0 0.55 0.51 -0.32 0.6 0.63 
MAP 0.72 0.75 0.34 0.53 0.40 0.41 0.16 0.14 0.35 0.15 0.27 
Note: The table shows a possible link between genes with high drug overlap, and the MAP values 
for ExGene configurations. The results are summarized per model. Some of the models show 
high correlation between their results and the degree of overlap (e.g. rand-vec oas-ExGene and 
ri_att oas-ExGene) which may help explain their higher-than-anticipated MAP.  Further details 










































Note: Effect of moving from using reference drugs that had representatives in the search 
spaces (Original) to the full reference set irrespective of whether the target drugs were 
represented in a space or not (Full Ref). Best results for attributional or relational categories 
are underlined, and best result overall is shown in boldface. On average the median MAP 




My main hypothesis was that relational similarity would be more effective than 
attributional similarity in finding drugs that interact with particular genes. To this end, for 
each category of relational similarity, I also developed an attributional counterpart. The 
results indicate that models based on relational similarity generally outperform models 
based on attributional similarity on this task, providing strong support for the utility of 
analogical reasoning (exemplified by relational similarity) in the task of identifying 
clinically relevant relationships in natural language text.  
A related hypothesis was that ExGene configurations would be advantageous for relational 





supported in part by the results, as the Random Indexing based relational model exhibited 
its best performance in ExGene settings, leveraging relationships involving other genes (I 
did not compare relational embedding techniques for InGene configurations, as the 
emb_rel model is only defined for ExGene). However, I also anticipated that attributional 
models would perform worse in ExGene settings (where cue drugs interact with other genes 
than the target gene). This was exemplified by the ri_att model, with a performance 
drop from a MAP of 0.46 in abo-InGene to 0.14 in abo-ExGene. However, emb_att 
surprisingly displayed the opposite behavior, where its performance improved upon 
moving from InGene to ExGene (0.23 to 0.41). This paradoxical behavior may be due to 
the fact that in many cases the genes may be functionally related to one another, a 
hypothesis that is further supported by the drug overlap among Gene Sheets explained 
previously. Further investigation is needed to fully explain this phenomenon, as it is not 
clear why this would occur with one attributional model, but not the other.   
A third hypothesis was that abo models would generally perform better than their oas 
counterparts. This hypothesis held true across the majority of the experiments (with one 
exception, ri_att oas-ExGene), suggesting that in emerging domains, where existing 
knowledge is limited, the best strategy for creating robust query vectors may be to use as 
many existing positive cues as possible. This finding is consistent with previous work on 
analogical reasoning using distributed representations of semantic predications (“concept 
relation concept” triples) extracted from the biomedical literature using SemRep (Trevor 





domain (Drozd et al., 2016). As more positive examples are found, their addition to an 
existing query vector will progressively add to the robustness of the query. 
Regarding the nature of the underlying representation, the emb_rel model consistently 
outperformed ri_rel both in oas and abo configurations. The emb_att model, 
however, was only marginally better than ri_att with oas-InGene, and in the case of 
abo-InGene, it fell short of this simpler model. This apparent disadvantage might be due to 
the context size for the two models. While the ri_att model used the whole Medline 
abstract, emb_att only used a small sliding window, which provides a limited scope, and 
may help explain the poor performance. Further research is needed to test this hypothesis, 
perhaps by providing a larger window for the neural embedding model, or adapting it to 
treat entire documents as contextual units.   
Another advantage of the emb_rel model over ri_rel was ease of generation, 
efficiency, and scalability. Embedding models represent individual concepts as vectors. To 
create the ri_rel search space, I had to first find and extract explicit drug-gene pairs 
from individual sentences, and then create bags-of-words from their intervening terms, a 
computationally demanding pre-processing step that took considerable effort to develop, 
and must be repeated whenever new information is added to the corpus. Furthermore, the 
resulting vector space is larger as each pair, rather than each entity, must be represented 
with a unique vector. Given both the level of development, execution effort, and overall 






A surprising finding amongst the results was the performance of the random vector based 
baseline model (rand-vec). I expected negligible performance, as random vectors are by 
design generated with a high probability of being mutually orthogonal or close-to-
orthogonal, and as such are not meaningfully similar to one another. While I obtained the 
expected results with InGene models, those for ExGene were surprisingly productive, 
particularly the median MAP of 0.27 for abo-ExGene. I believe this phenomenon is 
explained by the overlap between drugs across gene sheets, providing the model with same 
vector both as a seed and as target. This theory is supported by the fact that using the 
rand-vec model, I obtained better results with genes that shared many drugs with other 
genes than those which did not (e.g., FGFR1, FGFR2, FLT3, KDR, PDGFRA, RET). As 
shown in Table 13, there is a high correlation between drug overlap and rand-vec results 
in the ExGene category, 0.6 and 0.63 for oas-ExGene and abo-ExGene, respectively. The 
other baseline model was frequency, which I compared to the relational models. While 
with a median MAP of 0.35, the frequency model seems relatively strong in terms of 
its ability to find gene-related drugs, it outperforms neither ri_rel, nor emb_rel, 
indicating that these models are more effective than a simple count of co-occurrence in 
finding the desired relationships.  
Comparison with existing work 
The results are not directly comparable to prior work in different domains. The literature 
is relatively sparse on the application of neural concept embeddings in precision oncology, 





only one paper in the biomedical domain that concerns using neural word embeddings 
derived from unstructured text (as opposed to neural embeddings derived from semantic 
predications (Trevor Cohen & Widdows, 2017)) for analogical retrieval (Newman-Griffis 
et al., 2017), and this work does not compare attributional and relational models. As 
mentioned previously, EBC provides an alternative method to ri_rel for estimating 
relational similarity, however it is not directly comparable to my work, since my corpus 
has not been parsed for grammatical dependencies. Future work, however, includes parsing 
the corpus to find those dependency paths (or leveraging the set provided by the creators 
of EBC (Percha, Altman, & Wren, 2018b)) so that EBC can be used. As an attributional 
counterpart to EBC, Levy and Goldberg’s dependency based embeddings (Levy & 
Goldberg, 2014) can be considered.  
Another factor that complicates direct comparison with existing work involves exploration 
of the space of model hyperparameters, which often resulted in improved performance. 
Levy et al. provide an extensive description of the set of SGNS hyper-parameters that can 
be altered to improve the embedding results (Levy et al., 2015). Among the many 
parameters they explain, I chose to examine three – window size, sub-sampling threshold, 
and adding context vectors to word vectors. In line with previous work, I found that adding 
context vectors to word vectors consistently improved word embedding results (across all 
the cross validation configurations) (Levy et al., 2015).  Future work involves performing 






I faced two problems when dealing with drug-gene relationships in precision oncology. 
The first problem concerned term to concept mapping (performed by MetaMap), and the 
other had to do with finding relationships of interest. In the current project, I specifically 
focused on the latter to fulfil the primary goal of this research – comparative evaluation of 
different similarity models. Some drugs (119 out of 237 or 50%, Table 1) in the reference 
set were excluded from evaluation, either because they had no representative in vector 
space (e.g. because they were not mapped to CUIs by MetaMap,), or because they did not 
pass the drug filters that I used (which were also based on CUIs). An additional 19 drugs 
were excluded because of the co-occurrence filter. As such, some true positive results that 
would have been missed were excluded to allow a “fair” comparison of models.  
However, to estimate practical utility, the full reference set should be used. As shown in 
Table 14, penalizing the models for missing drugs that they do not represent results in a 
substantial drop in performance. More work is needed to address the limited coverage of 
therapeutically relevant agents, an issue I hope to address by replacing the concept 
extraction component of the system in the future. This may involve further expansion of 
MetaMap vocabularies, or substitution of an alternative method for the recognition of drug 
and gene entities that is not dependent on curated knowledge resources, which would be 
advantageous in emerging domains such as precision oncology. 
In addition, both the literature and the reference set used in this research were around 2-3 





spaces and reference sets used in information retrieval research projects in these domains 
if the resulting systems are to be practically useful.  
Furthermore, while I tried to follow the current literature in selecting model hyper-
parameters, the current work should not be considered an exhaustive test of these 
parameters. It is quite possible that other adjustments could further improve performance. 
Up to this point, I tested my assumptions and techniques using cross validation across a set 
constructed by a single team of PODS curators. So, the methods have not been tested in 
other contexts or for similar tasks. However, the PODS curators constructed the reference 
standard independently of the computational work and the main goal of this research was 
to compare different similarity methods and paradigms. In the next chapter I use seed drugs 
produced by NLP, to test the methods when used with an independent set of cues. This is 
an important step in terms of evaluating the utility of the developed methods when applied 










Chapter 5: Unsupervised identification of clinically relevant drug/gene relationships  
In the previous chapter, I compared the utility of a broad range of relational and 
attributional models for the task of finding relevant drug-gene relationships. In those 
experiments, both the “seeds” and the held out “answers” came from the same expert-
curated reference set. While this type of cross validation can serve to demonstrate the utility 
of the developed models, it can only be used in cases where some positive cues are already 
known to the system. In practice, this may not always be feasible. In this chapter I use cues 
that are extracted automatically from biomedical literature, using NLP, and evaluate the 
performance of attributional and relational models developed in Aim 1.  
Methods 
I used SemMedDB_UTH and isolated predications that were associated with the target 
genes in the reference set. I chose predications with predicate types 'INHIBITS', 
'INTERACTS_WITH', 'COEXISTS_WITH' that had any of the target genes as “subject”, 
and any drug (concepts with UMLS semantic types aapp, antb, clnd, horm, imft, nnon, 
opco, orch, phsu) as “object”. Table 15 shows the number of predications found for each 































































































299 1,992 116 329 319 286 1,124 778 328 299 289 256 184 87 89 21 74 
 
It must be noted that the predications are not unique to Gene Sheets, as different genes may 
share certain characteristics, and the same drug may target more than one gene. This is 
similar to the reference drug overlap phenomenon discussed in the previous chapter, where 
the unexpectedly high performance of some models (such as rand-vec) seemed to be 
associated with the overlap. Similarly, assertions that are repeated in the context of more 
than one gene may have a better chance of being accurately extracted.  
Next, I tested the best performing models from the relational and attributional categories 
from Aim 2 with these predications as seeds, and with all the other constraints the same as 
the main experiment. 
Configurations 
Unlike the models explained in Aim 2 where seeds and targets came from the same 
reference set, in this experiment the seeds (predications from SemMedDB_UTH) were 
from a different set than the reference set. Therefore, cross-validation (abo or oas) was 
neither defined, nor required, as the predications were used as seeds (known as 
Predications-As-Seed, “pas”) to find the targets. Arguably though, the pas model is more 





the predications concerned, is used as cue to find one drug in a single Gene Sheet at a time 
(InGene), or all the drugs in one Gene Sheet (ExGene). 
Results 
The results are summarized in Table 16. The best performing model in this experiment was 
embeddings relational model (MAP of 0.64), followed by the RI-based relational model 
(MAP of 0.31). Both the relational models outperformed their attributional counterparts. 
An important question concerned how these pas models would compare against their abo    
 
Table 16. Predications used as seeds 
Predications 































































































































































































































































































Note: With predications used as seeds, MAP per gene-model combination, and the 
median MAP per model across all the genes are shown. Best results for attributional or 
relational categories are underlined, and best result for each gene sheet and overall are 
shown in boldface. Other system parameters including the total number of drugs in the 
vector space, and the number of drugs in the reference set are identical to the main 
experiment from Aim 2. This experiment was only run for the best performing models in 





counterparts from the cross-validation experiment in Aim 2. The answer to this question 
could help elucidate the role of NLP (versus human experts) as the provider of cues in this 
task (although curation of the results would still require human input). As summarized in 
Table 17, the median MAP dropped an average of 0.13 across the five models when moving 
from abo to pas. 
 
 
Table 17. Comparing pas models with their abo counterparts 
Category Model / configuration 
Median 
MAP abo 
Median MAP  
pas 
Drop 
Relational ri_rel ExGene 0.53 0.31 0.22 
Relational emb_rel ExGene 0.75 0.64 0.11 
Attributiona
l 
ri_att ExGene 0.14 0.03 0.11 
Attributiona
l 
emb_att ExGene 0.41 0.35 0.06 
Baseline rand-vec ExGene 0.27 0.12 0.15 
 
 
Practical utility of the methods with predications as seeds 
I tested the models with the full set of available drugs in the reference set (394 therapeutic 
applications for drugs across 16 Gene Sheets, Table 9) with all the other constraints the 





across the five models (Table 18). The relational models still outperformed the attributional 
models, a finding consistent with those of the main experiment.  
 
Table 18. Full reference set (Full Ref) versus the original configuration. 






Relational ri_rel pas-ExGene 0.31 0.12 0.19 








0.35 0.16 0.19 
Baseline rand-vec pas-ExGene 0.12 0.05 0.07 
Note: Best results for attributional or relational categories are underlined, and best result 




Summary of the findings 
Table 19 summarizes the findings across all the experiments in this chapter. As discussed, 
the best performing model overall was Relational Embeddings (emb_rel) across the four 








Table 19. Summary of the overall findings. 
 Controlled Reference Set 
- 16 Genes 
- 163 Drugs  
- shared by search spaces  
- limited to co-occurrence 
Full Reference Set 
- 16 Genes 
- 394 Drugs 
- all drugs 
Supervised: Within Reference Set 
Best model 
Relational embeddings: 0.75 
(abo-ExGene) 







Random baseline 0.27 0.15 
Unsupervised: Predications as Seed 
Best model 
Relational embeddings: 0.64 
(pas-ExGene) 







Random baseline 0.12 0.05 
Note: Relational embeddings model outperformed both the RI-based relational models 








In this chapter, I showed that using the developed methods in an unsupervised manner still 
produces results that are consistent with my main hypothesis. On the other hand, when 
testing with the full reference set, the best performing model in this approach had a clear 
advantage over the randomly created baseline (MAP of 0.27 vs. 0.05 for the random 





relative utility of the methods for this task. The practical utility becomes more important 
when dealing with a new domain where there is little prior knowledge available. Using the 
system in those scenarios will provide the curators with some initial cues that will then help 










Chapter 6: Contributions, conclusion, and future direction 
In the work described in this dissertation, I compared relational and attributional similarity 
measures for their utility in finding clinically relevant drug/gene relationships in the 
context of precision oncology, which presents unique challenges on account of the pace of 
evolution of clinically actionable knowledge. I found that models based on relational 
similarity outperformed models based on attributional similarity on this task. This finding 
consistently held true in multiple experiments across the two large paradigms of 
distributional semantic methods, Random Indexing  (RI) (M. Sahlgren, 2005), and neural 
word embeddings (NWE) (Mikolov, Chen, et al., 2013). This is the first time methods of 
relational and attributional similarity have been systematically compared in this manner, 
and as the methods can be applied to identify any sort of relationship for which cue pairs 
exist, my results suggest that relational similarity may be a fruitful approach to apply to 
other biomedical problems. Furthermore, I found models based on NWE to be particularly 
useful for this task, given their higher performance than RI-based models, and significantly 
less computational effort needed to create them. 
In my preliminary work, I developed the AIMED system (Fathiamini et al., 2016) to find 
relevant drug-gene relationships for precision oncology, using NLP and sentence based co-





shortcomings of knowledge based NLP methods and co-occurrence statistics, especially 
with early stage drugs, which provided the practical motivation for this dissertation. The 
current research takes an important step toward a better AIMED application, by providing 
it with more robust alternative techniques that can potentially address some of its 
shortcomings.  
In the section that follows I will proceed to reevaluate my main hypothesis in the light of 
the research findings I have documented in the preceding chapters.   
Assessment of hypotheses 
My main hypothesis was that measures of relational similarity would be of greater utility 
than attributional similarity for the task of identifying biological relationships that may 
answer clinical questions in the context of rapidly changing domains. My results provide 
strong support in favor of this hypothesis, with estimates of relational similarity yielding 
better performance than comparable measures of attributional similarity across multiple 
experiments.  
Additionally, during the course of these experiments, I developed other hypotheses that 
were closely related to the main hypothesis. I found out that the best strategy to maximize 
the robustness of a similarity-based query across a large vector space was to add vector 
representations of as many cues as possible to construct a query vector. This finding was 
supported by the observation that my abo models (in which all the existing cues would 





(where cues consisted of only one cue). This finding is consistent with prior research both 
in the biomedical (Trevor Cohen et al., 2011), and the general domain (Drozd et al., 2016). 
A related hypothesis with potential practical implications for search in domains with 
emerging knowledge is that when looking for drugs that target a gene, using information 
about the relationships involving other genes as cues helps improve the accuracy of system 
responses in relational models. In fact, relational models actually performed better with 
cues concerning other genes, than with cues derived from held-out components of the gene 
sheet under evaluation. This hypothesis was supported by the results showing that the 
ExGene configurations consistently outperformed the InGene settings, when used with 
relational models.  From a practical point of view, this finding means that prior knowledge 
of drug-gene relationships in general can facilitate the search of drugs targeting a gene of 
interest. Thus, relational models have more information to draw upon than attributional 
models, and the search for drugs targeting a specific gene can proceed without the need for 
an agent that is already known to be effective to serve as an exemplar.   
Theoretical Contribution 
Similarity is a fundamental cognitive construct. (Medin et al., 1990) Similar concepts are 
thought to belong to the same conceptual category in the human mind (Medin et al., 1993), 
new concepts are thought to be assigned to existing categories based on how similar they 
are to concepts exemplifying these categories, and evidence suggests that memory relies 
on similarity operations to retrieve concepts. (Medin et al., 1993) In my experiments, I 





similarity. This is consistent with cognitive theories of analogy, which suggest that 
relational similarity is the most important aspect of similarity for analogy processing and 
retrieval.(HOLYOAK & THAGARD, 1989; Medin et al., 1990, 1993) My results indicate 
that models based on relational similarity generally outperform models based on 
attributional similarity in the task of identifying clinically relevant relationships in natural 
language text, providing strong support for the utility of analogical reasoning for this task. 
In other words, my work shows that the same mechanisms that have been proposed to 
explain experimental data on analogical retrieval can also be leveraged for practical tasks 
in the biomedical domain.  
Informatics Contribution 
This research compares methods of relational and attributional similarity, using methods 
of distributional semantics (Trevor Cohen & Widdows, 2009) when applied to finding 
desired relationships in emerging biomedical domains, and specifically, precision 
oncology. I used techniques of Random Indexing (M. Sahlgren, 2005) and neural word 
embeddings (NWE) (Mikolov, Chen, et al., 2013), and was able to establish the latter as 
the technique of choice for this task across multiple experiments. To the best of my 
knowledge, the relative utility of relational and attributional similarity for tasks of this 
nature has not been systematically evaluated in biomedicine previously. Moreover, the 
utility of NWE-based relational similarity in finding concept pairs using exemplar cue pairs 
has not been explored in the context of emerging biomedical knowledge in general, and 






The results of this research can guide the design and implementation of biomedical 
question answering and other relationship extraction applications for precision medicine, 
precision oncology and other similar domains, where there is rapid emergence of novel 
knowledge. The methods developed and evaluated in this project can help NLP 
applications provide more accurate results by leveraging corpus based methods that are by 
design scalable and robust. 
Precision oncology is rapidly evolving and scientists at cancer centers spend a significant 
amount of time and effort maintaining knowledge bases that directly affect clinical decision 
making processes.(Meric-Bernstam et al., 2013) As a preliminary step to this research, the 
AIMED project showed promising results in terms of helping expert curators find some of 
their desired answers in the literature. At the same time, AIMED also revealed some of the 
shortcomings of the Boolean retrieval system leveraging semantic constraints and co-
occurrence frequency. The results of the current research are based on ranked retrieval by 
distributional techniques, and so, they are not directly comparable to the Boolean system 
of AIMED. Nonetheless, they elucidate the ways in which the applied models and 
configurations can be optimized to accommodate the unique characteristics of the problem 
domain of precision oncology.   
In my final experiments in this project, I developed and evaluated a method in which cues 
were provided by NLP methods, without human intervention. This has important practical 





of relevant information from the literature is automated, which allows human experts to 
focus only on the information that has already been filtered, potentially saving time and 
effort.  
It must be noted that the intended users for this system are annotators rather than clinicians. 
While the methods developed in the research have shown promising results, they are not 
yet at a level that can be used for direct clinical decision support without human 
supervision.  
Future Steps 
Future steps involve finding ways to improve the accuracy of my methods, test in other 
domains, and find ways to increase its practical usefulness.  
There is great room for improvement in terms of increasing the accuracy of the results by 
developing methods that can incorporate more knowledge sources (like clinical trials, 
commercial drug company web sites, drug pipelines, etc.) to increase the breadth of 
available information. Both my preliminary work (AIMED) and the main research relied 
on ontology based named entity recognition (NER), using MetaMap (Aronson, n.d.). This 
approach posed limitations in terms of  the breadth of the supported vocabulary, and as 
such, application of more accurate NER technology that is already available (Leaman & 
Gonzalez, 2008; Leser & Hakenberg, 2005) is a priority. Exploring other informatics 
approaches to build the search space, such as using dependency paths  (as explained in the 
work by Percha (Percha & Altman, 2015)) to define relationships is another area of future 





search space parameters, to accommodate the unique characteristics of rapidly evolving 
domains. The methods discussed in this dissertation have only been applied to the domain 
of precision oncology. Future work involves testing the techniques in similar domain where 
knowledge is rapidly evolving. To increase the practical usefulness of the system, the 
development of an interface to permit users to adjust query constraints in accordance with 
their preferences concerning workload and completeness, is an important step toward 
improving the system usability.   
Conclusion 
In this research, I compared relational to attributional measures of similarity across a range 
of representational approaches, for their ability to recover therapeutically important drug-
gene relationships. Relational similarity performed better than attributional similarity for 
this task, demonstrating its utility as a means to identify clinically important biomedical 
relationships. These results have implications for the application domain of precision 
oncology, as they provide validation for methods that identify clinically-relevant drug/gene 
relationships. Furthermore, these methods should be applicable to the identification of 
biomedical relationships of any type where exemplar cues are available to seed the 
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